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Despite recent progress in the diagnosis of Tuberculosis (TB), the chemotherapeutic
management of TB is still challenging. Mycobacterium tuberculosis (Mtb) is the
etiological agent of TB, and TB is classified as the 13th leading cause of death globally
[WHO 2021]. 558,000 people were reported to develop multi-drug resistant TB globally
[WHO 2020]. Our research focuses on targeting Methionine Aminopeptidase (MetAP),
an essential protein for the viability of Mtb. MetAP is a metalloprotease that catalyzes the
removal of N-terminal methionine (NME) during translation of protein [Giglione et al.,
2003]. This essential role of MetAPs makes this enzyme an auspicious target for the
development of novel therapeutic agents for the treatment of TB. Mtb possesses two
MetAP1 isoforms: MtMetAP1a and MtMetAP1c, which are vital for Mtb viability, hence
a promising chemotherapeutic target for Mtb infection [Zhang et al., 2009; Olaleye et al.,
2010; Griffin et al., 2011; Vanunu et al., 2019]. In our study, we cloned, overexpressed
recombinant MtMetAP1c, and investigated the in vitro inhibitory effect of OJT008 on
cobalt and nickel ion activated MtMetAP1c. The compound’s potency against replicating
and multidrug-resistant (MDR) Mtb strains was also investigated. The induction of the
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overexpressed recombinant MtMetAP1c was optimized at hours with a final
concentration of 1mM Isopropyl β-D-1-thiogalactopyranoside. The average yield for
MtMetAP1c was 4.65 mg/L of Escherichia coli culture. A preliminary MtMetAP1c metal
dependency screen showed optimum activation with nickel and cobalt ions at 100µM.
The half-maximal inhibitory concentration (IC50) values of OJT008 against MtMetAP1c
activated with CoCl2 and NiCl2 were in the micromolar range. Our in silico study showed
OJT008 strongly binds to both metal activated MtMetAP1c, as evidenced by strong
molecular interactions and higher binding score thereby corroborating our result. Thus,
validating the pharmacophore’s metal specificity. The potency of OJT008 against both
active and multidrug-resistant (MDR) Mtb was in the low micromolar concentrations,
correlating well with our biochemical data on MtMetAP1c inhibition. These results
suggest that OJT008 is a potential lead compound for the pre-clinical development of
novel small molecules for the therapeutic management of TB.
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CHAPTER 1

INTRODUCTION
1.1 Tuberculosis disease
Tuberculosis (TB) is documented as one of the oldest infections [Tornheim et al., 2019]
known to have affected humans for thousands of years [Hershkovitz et al., 2015]. The
etiological agent for TB is Mycobacterium tuberculosis (Mtb) [Gordon et al., 2018, WHO,
2021]. The etiology of the disease was unknown until March 24, 1884, when Dr. Robert
Koch reported the discovery of the bacillus name, Mtb [Sakula et al.,1982]. The pathogen
is characterized by a microscopic appearance in tissues as caseating granulomas. TB may
affect the lungs (pulmonary TB) and, in some cases, other parts of the body
(extrapulmonary TB) [Lee et al., 2015].
The Mtb genus is aerobic, majorly non-motile, and the morphology of the colony formed
varies in different species ranging from pigmented to non-pigmented, rough to smooth
[Pfyffer et al., 2015]. It has a distinguishable cell wall from a preponderance of prokaryotes
and shares prominent features with gram-negative bacteria, albeit a gram-positive
organism [Minnikin et al., 1991; Brennan., & Nikaido., 1995]. The primary constituent of
the cell wall is the peptidoglycan consisting primarily of N-acetylmuramic acid and Nacetylglucosa
1
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mine alternating polymers [Brennan., & Nikaido., 1995]. About 90% of the world's
population infected with TB are adults, of which the predominant sex is the male
gender [ WHO, 2021]. Mtb transmission is airborne, and the droplet nuclei, diameter 1–5
µm, containing Mtb from the sneeze or cough of Infectious patients and through
complement factors bind to the alveolar macrophage cell wall of the host, reducing the
acidity of the cell wall and phagosome of its host cells. As a result, the phagosome
maturation is impeded, and this promotes Mtb bacilli multiplication and eruption, thereby
propagating infection in the host [Raviglione et al., 2018]. There are 2 types of TB
conditions: active TB and latent TB. Active TB is characterized by a multiorgan disease
condition caused by either reactivation of TB from its latent state, latent TB (LTB)
condition, or through Mtb primary infection. Inhaled Mtb can be killed by the host alveolar
macrophage of the host; however, in an immunocompromised state, the host becomes
infected with active TB. It affects mainly the lungs- pulmonary TB, but can also affect
other parts of the body, extrapulmonary TB, which includes the musculoskeletal system,
reproductive system, gastrointestinal system, lymphoreticular system, the liver, and skin
[MacPhersonet al., 2020]. The World Health Organization (WHO) reported 10 million
people were infected with active tuberculosis in 2020 [WHO, 2021]. Between 5 - 10% of
Mtb infected patients develop active TB within 2 to 5 years [ Comstock et al., 1974;
Vynnycky et al., 1997; Anderson et al., 2018]. In the 21st century, "LTB refers to a host
who is TB immunoreactive in the absence of TB disease." [Behr et al., 2021]. LTB is
asymptomatic in its clinical manifestation, which can only be detected through blood tests
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or tuberculin skin tests. Globally, 1 in 4 persons, approximately 2 billion people, are LTB
infected [WHO, 2021). Reactivation occurs in immunocompromised people with risk
factors such as diabetes, alcohol, smoking, and undernutrition.
Human immunodeficiency virus (HIV)-infected patients also have a higher risk of
developing TB [Havlir, D. V., & Barnes., 1999]. LTBI is treated majorly with Rifapentine
[Harley et al., 2017]. In the 1990s, an outbreak of drug-resistant TB occurred in New York,
killing about 80% of infected hosts [Elander, 2005].
About 0.05 to 5% of TB cases are the extrapulmonary type of infection [Nanda et al., 2011.
The major type of extrapulmonary TB includes tubercular Lymphadenitis [Hegde et al.,
2014], pleural TB, abdominal TB [Sharma et al., 2004], central Nervous System TB [Zunt
et al. 2018], bone and Joint TB [Pigrau-Serrallach et al., 2013], genito-urinary TB, and
miliary TB. The three primary diagnoses for TB include tuberculin skin test, chest X-ray,
and mycobacterial cultures [Alzayer et al., 2021].
The pillars and components adopted by the WHO member countries to eradicate TB
globally include early diagnosis, patient support, and treatment of TB patients, including
the drug-resistant TB, management of TB comorbidities, and prophylaxis measures,
including vaccination for persons in and from TB endemic regions [WHO, 2021]. Some
countries have successfully reduced the TB burden to less than 10 cases and one death out
of 100,000 population per annum [WHO, 2021]. However, research work, including
discovering new drugs and vaccines, is still needed to reduce the global TB incidence.
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1.2 TB as a global health issue
Tuberculosis (TB) is the 13th leading cause of death globally [WHO, 2021]. It is a
communicable and highly infectious disease. As of 2020, TB was predicted to be the
second top leading source of death arising from single infectious diseases, below the rank
of coronavirus disease 2019 (COVID-19) [Glaziou P et al., 2020]. Approximately 25% of
the world population is infected with latent TB, approximately 2 billion people [ WHO,
2021]. This implies 1 in 4 persons have asymptomatic and non-infectious Tuberculosis
(TB) while 5-10% of TB infected patients are at risk of developing active TB. The number
of TB-caused deaths recorded in 2020 was higher than in 2019. There was an increase in
TB deaths from 1.2 million in 2019 to 1.3 million in 2020. World Health Organization
(WHO) modeling projections forecast that the number and incidents and death related to
TB will be comparatively higher in 2021 and 2022 [WHO, 2021]. Global TB deaths rose
for the first time in a decade in 2020 due to the COVID-19 pandemic. Health care resources,
diagnostic tools, lockdown, and funding were diverted from TB management during the
COVID-19 crisis [WHO, 2021]. The challenges of controlling TB spread are still globally
divided into five major areas: the demand for WHO to increase short course (DOTS)
programs, Directly Observed Therapy, insufficient TB diagnostics and treatments, TB-HIV
coinfection, and MDR-TB [Murray et al., 2006]. The increase in TB deaths occurred
mainly in the 30 high Burden TB Countries [WHO, 2021b]. Although the United States
(U.S) TB incidence for 2020 was 2.2 cases per 100,000 persons [Deutsch-Feldmanet al.,
2021], the significant risk factor of United States TB cases is the result of non-U.S. birth
accounting for greater than 70% of TB cases in the United States [Miramontes et al., 2015].
Although there has been a global reduction of the incidence rate of TB and cases over the
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years, the rate of reduction is not sufficient to achieve the End TB Strategy's first milestone:
a 20% reduction of the global TB incidence, 35% reduction of TB deaths, from 2015 to
2020 [WHO, 2015]. Currently, an average 2% global decline in TB incidence rate is
recorded, which is below the target of 17% average annual TB incidence decline goal from
2020 to 2035 by the WHO End TB Strategy initiative [Stop TB Partnership et al., 2015,
Chaw et al., 2020]
The effort to eradicate TB has been challenging due to reduced drug discovery of novel
antibiotics to combat TB. Intensified research and innovation are critical to meeting the
WHO End TB Strategy targets for 2030 and 2035. The challenges in eradicating TB disease
include the emergence of Mtb resistance to standard current anti-TB therapy. These include
multidrug-resistant, extensively, and totally drug-resistant strains of Mtb [Cole et al., 1998;
Fauci et al., 2008, Haydel, 2010]. It is crucial to develop antimycobacterial that inhibit
novel Mtb drug targets and mechanisms of action [Theuretzbacher et al., 2019]. Another
factor in obtaining efficient TB medication compliance is considering novel
antimycobacterial that will constitute less pill burden and reduce the duration of the drug
regimen. The current regimen consists of a cocktail of drugs for drug-sensitive TB
treatment for about six months [Munro et al., 2007, WHO, 2021].
Recent molecular technology involving the whole genome sequencing analysis of Mtb has
improved the tools and strategy in developing novel antimycobacterial agents to combat
Mtb drug-resistant types [Cole et al., 1998; Sassetti et al., 2003; Abrahams et al., 2012].
Therefore, the need to develop vaccines and novel drugs with a simpler and shorter duration
of treatment to treat about 2 billion people infected with Mtb is urgent. Since the approval
of rifampicin by the United States Food and Drug Administration (FDA) in 1971 [Sensi,
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1983], the discovery and development of an antimycobacterial pipeline have experienced
a pause. In August 2020, 25 antibiotics were developed for active, multidrug-resistant, and
TB infection in phase 1-3 clinical phase [WHO, 2021]. Sixteen of these drugs are new
chemical entities, and two have received accelerated regulatory approval. The FDA has
approved three drugs, bedaquiline, delamanid, and pretomanid, while 6 are repurposed
drugs [WHO, 2020]. Therefore, the need to discover novel pharmacophores that inhibit
new drug targets for Mtb, have a new mechanism of action, and are potent against drugresistant Mtb is significantly vital.
1.3 Historical background of tuberculosis
TB has plagued humanity from prehistory to history, with Mtb suggesting killing more
people throughout history than other infectious pathogens. Ancient, excavated writings
from India, China, Egypt, Greece, and Babylonia attested to the different names given to
TB. The oldest detection of Mtb was in the remains of Bison about 17,000 years ago in
Wyoming [Rothschild et al., 2001]. However, the knowledge of whether TB originated
from bovines and transferred to humans or if both humans and bovines had different TB
ancestry was obscure [Pearce-Duvet et al., 2006]. A comparative study of the genes of
human and animal M. tuberculosis complex (MTBC) suggested animals did not infect
humans; however, TB infection could date as far back as the Neolithic revolution period
[Comas et al., 2009]. TB Paleopathological proof existed as far back as 8000 BCE with the
discovery of bony tuberculosis, during the 5800 BCE Neolithic period, and by 2400 BCE
in Egyptian mummies [Herzog, 1998; A Boire, 2013], TB has existed since ancient times
[Martini et al., 2020]. Previous postulations that the genus Mycobacterium originated more
than 150 million years ago [Hayman, 1984]. Gutierrez et al. postulated that the progenitors
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of Mtb infected prehistoric hominids and were about 3 million years ago present in east
Africa [Gutierrez et al., 2005]. Contemporary Mtb complex members, including
Mycobacterium africanum, Mycobacterium Bovis, and Mycobacterium canettii, originated
from one African progenitor about 13 to 15 millennia ago [Gutierrez et al., 2005; Kapur et
al., 1994; Brosch et al., 2002]. The current strains of Mtb present are categorized into six
major clades, all of which are present in east Africa but scattered across the globe [Gagneux
et al., 2006]. However, the archeological evidence to support TB origin from East Africa
was lacking, albeit this evidence was documented in Egypt about 5000 years ago. TB
characteristic Skeletal abnormalities were seen in Egyptian mummies and portrayed in
Egyptian art [Cave et al., 1939, Morse et al., 1964, Morse et al., 1967; Zimmerman et al.,
1979]. Current Mtb DNA amplification from Egyptian mummified tissues further
elucidated the etiological agents for ancient skeletal diseases [Nerlich et al., 1997; Crubézy
et al., 1998]. Schachepheth was the old Hebrew word for TB in Leviticus and Deuteronomy
in the bible [Daniel et al., 1999]. Ancient migration from Africa [Gibbons et al., 2001] to
China, India [Veith et al., 1969], Europe, and the Americas propagated the spread of TB
across the globe [Daniet, 2000]. From the ancient empires and kingdoms, antiquity efforts
to name and describe TB have ensued. The old Grecian, Father of allopathic medicine,
Hippocrates, called TB phthisis and 'consumption' [Meachen, 1936, Daniel, 1997, Herzog
et al., 1998] and described it as a disease of dry seasons from the 17th to 18th century. In
Europe, it was called the great white death or white plague [Dormandy, 1999; Rene &
Dubos, 1953], robber of youth [Segen, 1992], King's evil or Scrofula [Rothman et
al.,2001]. During Laennec's era, the high mortality rate of TB in Europe made the disease
an epidemic with an annual mortality rate of 1000- 1000 per 100,000 people [Daniel, 2006].
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In Wales and England, about 4 million people aged 15 to 34 died from TB between 1851
and 1910 [ Welshman, 2012]. By the end of the 1800s in London, 25% of her citizens died
of TB. This death number was comparable to North American big cities.
Over the centuries, the cause of TB has been debated. Girolamo Fracastoro (1476-1553)
was the first to postulate the cause of TB to an invincible organism which Benjamin Marten
1720 called a microscopic living organism, "animacula," thereby corroborating the
previous theory of Anton van Leuwenhoek (1632-1723). Robert Koch received a Nobel
Prize Lecture in 1905 for discovering tubercle bacillus as the etiological agent for TB. He
acknowledged the importance of social welfare for Germans infected with TB [Koch,
1905]. In addition to Koch's findings in TB discovery Rudolf Ludwig Karl Virchow, an
acclaimed father of social and hygiene medicine, 1821-1902, discovered the multifactorial
genesis of the TB disease. He found that besides the infection by the pathogen bacillus,
other multi factors contribute to the development of active TB status.

1.4 TB in North America continent
The TB incidence in the U. S has experienced a steady decrease since 1993 [Centers for
Disease Control and Prevention report 2020]. This trend is because of the nation's
Tuberculosis Elimination and Control Programs geared towards diagnosis, treatment, and
prevention of TB. An identical trend in TB incidence has equally been reported globally
[Kwak et al., 2020]. By 2021 7,163 TB cases in the District of Columbia (DC) and 50 states
were reported by CDC's National Tuberculosis Surveillance System in the United States
[Deutsch-Feldman et al., 2021]. The observed cases are a 20% reduction in the TB cases
reported in 2020 (TB incidence: 2.2 cases per 100,000 persons) as compared to the previous
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2019 (TB incidence: 2.7 cases per 100, 000 persons) [Deutsch-Feldman et al., 2021] Figure
1. Less than 1 case per 1,000,000 population is the TB elimination threshold, approximately
330 cases of TB per year based on the current U.S population. The U.S annual TB annual
decline is still insufficient to achieve the WHO new global strategy (End TB) Figure 2

Figure 1: Tuberculosis disease cases and incidence, by birth origin, — United States,
2010–2020.
Adapted from Deutsch-Feldman, M., Pratt, R. H., Price, S. F., Tsang, C. A., & Self, J. L.
(2021). Tuberculosis — United States, 2020. MMWR Surveillance Summaries, 70(12),
409–414. https://doi.org/10.15585/mmwr.mm7012a1
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Figure 2. Progress Towards TB Elimination, United States, 1982–2020 [CDC, 2020]
Adapted from Centers for Disease Control and Prevention. (2021). Tuberculosis in the
United States 2020 Slide Set. https://www.cdc.gov/tb/statistics/surv/surv2020/default.htm

An average 2-3% annual decrease in TB incidence [CDC, 2019]. Mid-year U.S. Census
Bureau population in the United States 8 states recorded an increase in TB cases, and no
changes were reported in 3 states, while 39 states and DC reported a decrease. East North
central had the largest TB incidence decrease (−25%) concerning the geographical
locations. Alaska reported the highest incidence (7.9 cases per 100,000 persons) and
California reported the highest cases (1,703) in 2020 [Deutsch-Feldman et al., 2021].
According to the federal guidelines, TB case and incidence reports were categorized under
birth origin and self-acclaimed race/ ethnicity, United States, 2017–2020. Under birth of
origin, in 2019 and 2020 consecutively, 70% of TB cases were reported amongst non–U.S.-
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born persons. The TB incidence in both non- U.S born persons (14.2 to 11.5 cases per
100,000 persons) and U.S born (0.9 to 0.7 cases per 100,000 persons) decreased from 2019
to 2020 [Deutsch-Feldman et al., 2021]. 10 % of all non–U.S.-born persons with TB cases
in 2020 received a diagnosis less than a year during their stay in the United States,
comparatively lower than the mean 16% value from 2015–to 2019. The change in TB
incidence is indicative of a change in the pattern of immigration into the United States in
2020.
The changes in immigration and travel patterns during 2020 could not effectively explain
the trend of TB cases decreasing. Nonetheless, the high proportion of TB cases reported by
people living in the United States for more than ten years [Tsang et al., 2020] and the
significant decrease in TB cases for both U.S born and non-U. S born people. This decrease
may be attributed to the implemented protocols designed to reduce the spread of COVID19 globally, indirectly reducing TB spread in 2020. Another plausible reason is the delayed
or under-diagnosed TB cases arising from reluctance to seek medical treatment during
COVID-19 [Czeisler et al., 2020].
The success of TB eradication in the United States experienced a deceleration in recent
years which is compounded by the pressure on present public health care, control services,
and prevention arising from the COVID-19 pandemic. 85% of TB diseases in the United
States were discovered through genotyping to be through the reactivation of latent TB
[Yuen et al., 2016]. Findings from genotyping of Mtb isolates suggest that an estimated
85% of TB cases in the U.S are attributed to reactivation of latent infection with Mtb that
was acquired >2 years prior [Mirzazadeh et al., 2021].
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A study by Mirzazadeh et al. showed that the effective way of preventing TB disease in
the United States is through the treatment of LTBI [Mirzazadeh et al., 2021]. There is a
need to increase the number of United States TB control efforts. A 1% decline in TB cases
were recorded in the United States from 2018 (9,021 cases) to 2019 (8,920), a fourth
consecutive year decrease. Nonetheless, the TB elimination goal of 1 case per 1 million
people remains far from being attained. The TB rate (2.7 per 100,000) as of 2020 in the
U.S is 27 times higher than the global target [CDC, 2020].

Figure 3. New CDC data highlight the need to strengthen the U.S.
Adapted from Centers for Disease Control and Prevention. (2020). Progress Toward
Tuberculosis Elimination Has Slowed in Recent Years – March 25, 2021. Retrieved from
https://www.cdc.gov/nchhstp/newsroom/multimedia-resources/tb-multimediaresources.html
About 13 million people are estimated to have LTBI in the United States in 2020, with an
estimate of 10% progressing from latent to active TB in their lifetime [CDC, 2021]. Ten
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drugs have been approved for TB treatment in the United States by the FDA. By 2018, the
treatment regimen for LTBI recommended by CDC in the United States includes
rifapentine, isoniazid, and rifampin [CDC, 2018].
TB drug resistance is a concern both globally and in the United States. Fewer than 100
cases of MDR-TB and XDR-TB. Four hundred fifty-six cases of isoniazid resistance were
reported in the United States in 2020, of which 9.5% of cases were recorded amongst nonU.S.–born persons and 4.8% of cases among the U.S.-born population Figure 2. [CDC,
2020a]. Only 1 case of XDR-TB was reported in the United States.
1.4.1 Latent Tuberculosis Infection Treatment Regimens
Fifty-six cases of MDR-TB were reported for 2020 in the United States: 0.2% and 1.3% of
the MDR-TB cases were reported from U.S.-born and non-U.S.–born populations [CDC,
2020b].
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Figure 4. Latent tuberculosis infection treatment regimens. Choosing the Right
Latent TB Infection Treatment Regimen [CDC, 2021].
Adapted from Centers for Disease Control and Prevention. (2021). Treatment Regimens
for Latent TB Infection (LTBI). Retrieved from
https://www.cdc.gov/tb/topic/treatment/ltbi.htm
TB is reported in the United States; however, the economic cost, duration to complete an
anti-TB regimen, shrug adverse and side effects remain a burden. Eradication of TB in the
United States is to have 1 case of TB per 1 million of her population. CDC's commitment
to completely eradicate TB in the United States includes expanding diagnosis and drug
treatment initiatives for LBTI patients.

1.5 Current TB drug therapy
Current TB drug therapy consists of a combination of several drugs with a treatment
duration of about six months for Drug sensitive TB type to a range of 6-20 months for
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MDR-TB or/and RR-TB. Efficacious TB drugs were first discovered and developed in the
1940s with a recommended treatment regimen of 6 months for the four first-line anti-TB
drugs: isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin. The FDAapproved antitubercular medications for Mtb infections include ethambutol, pyrazinamide,
rifampicin, and isoniazid [Ben Amar et al., 2015].
Table 1. Current antituberculosis drugs

Abbreviations: DOT, directly observed therapy; EMB, ethambutol; HIV, human
immunodeficiency virus; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin
Adapted from “Official American Thoracic Society/Centers for Disease Control and
Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment
of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases”, by Nahid, P., Dorman, S.
E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., … Vernon, A. October
2016. Oxford University press. https://doi.org/10.1093/cid/ciw376

The duration of the drug regimen depends on the type of TB infection: latent or active TB
[Parekh et al., 2013]. MDR-TB is a terrifying complication in TB drug treatment [Unissa
et al., 2016]. MDR-TB is peculiar to its resistance to first-line anti-TB: isoniazid and
rifampicin [Unissa et al., 2016], and its therapy is steadily evolving [Bloom et al., 2017].
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The common second-line TB drugs recommended for MDR-TB include capreomycin,
amikacin, and kanamycin injectable [Bloomet al., 2017]. The following fluoroquinolones
are also prescribed as second-line TB therapy for MDR-TB: gatifloxacin, levofloxacin, and
moxifloxacin [Berning, 2001, Moadebi et al., 2007]. The recent FDA- approved drugs for
MDR-TB bedaquiline, pretomanid, and linezolid [Barryet al., 2017; Mase et al., 2020;
Andrei et al. 2019; Riccardi et al., 2017]. The treatment regimen for MDR-TB has a longer
duration than the First-line TB therapy, is more expensive, and poses the dangers of drug
side effects.

Figure 5. Second-Line Treatments and Multidrug-Resistant Tuberculosis. Adapted
from “Tuberculosis Drugs and Mechanisms of Action” by the National Institute of
Allergy and Infectious Diseases. 2016. https://www.niaid.nih.gov/diseasesconditions/tbdrugs

Extensively multi-drug resistant tuberculosis (XDR-TB) is another rare but complicated
type of TB resistant to medications resistant to first-line TB medications: Isoniazid and
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rifampicin, one of the three aminoglycosides from the second-line medication and one of
the fluoroquinolones [Cang et al., 2013; Dheda et al., 2017].
Several anti-TB drugs are currently under development (Table 2.) The NAID is currently
supporting the development of Pretomanid, Linezolid, SQ-109, Sutezolid, and
Meropenems. New Treatment regimens consisting of drug combinations for drug-resistant
and drug-sensitive TB are under phase II and phase III trials.

Figure 6. Extensively Drug-Resistant Tuberculosis (XDR TB) - Options for
Treatment [CDC, 2020]. Adapted from “Tuberculosis Drugs and Mechanisms of
Action” by the National Institute of Allergy and Infectious Diseases. 2016. Retrieved
from https://www.niaid.nih.gov/diseases-conditions/tbdrugs
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Table 2. New Mtb drugs and their mechanisms of action in different clinical trial
phases [Wang et al., 2021]

Adapted from “Addressing the Challenges of Tuberculosis: A Brief Historical Account”
by Al-Humadi, H. W., Al-Saigh, R. J., & Al-Humadi, A. W. (2017, September 26),
Frontiers in Pharmacology. Frontiers Media S.A. Retreived from
https://doi.org/10.3389/fphar.2017.00689
The mechanism of action of TB drugs varies as the drugs inhibit different targets found in
Mtb biology. These include inhibition of nucleic acid synthesis, protein synthesis, and cell
wall synthesis.
There are challenges to using second-line anti-TB drugs for MDR-TB [Iseman, 1993]. The
challenges exist with the use of current antitubercular drugs. The non-compliance to
treatment due to the long duration of the regimen, high pill burden, and complexity of
treatment leads to suboptimal efficacy of drugs resulting from drug resistant cases
[Karumbi et al., 2015]. Secondly, the adverse drug reaction from TB medications also
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contributes to the non-adherence to the drug [Chan et al., 2002]. TB-HIV co-infection cases
constitute a challenge in TB eradication due to high pill count, additive toxicity profile,
and drug-drug interaction between rifampicin and the antiretrovirals, posing the challenge
of medication adherence [Narita et al., 1998]. The countries with limited resources, where
a higher number of MDR-TB cases exist, are unable to procure second-line anti-TB
medication because of its high cost in comparison to first-line anti-TB drugs.
1.6 Current global status of drug-resistant TB
According to WHO, cases of drug-resistant TB are categorized into 5: isoniazid-resistant
TB, MDR-TB, RR-TB, XDR-TB, and pre-extensively drug-resistant TB (Pre-XDR-TB)
[WHO TB global report 2021]. Totally drug-resistant TB (TDR-TB) is another type of
drug-resistant TB that the WHO does not recognize.
TB resistance to the first-line anti-TB isoniazid, isoniazid-resistant TB, is the most
common type of drug-resistant TB case globally. Mtb isoniazid-resistant strains usually
have mutations of ndh, katG, kasA, ahpC, and inhA [Silva et al., 2003]. WHO reports 7.2%
average isoniazid-resistant TB and 11.6% in previously treated and current treated TB
cases [WHO, 2019]. Sadly, although the global burden of Isoniazid-resistant TB has been
decreasing over the years, this trend is present in the United States despite the decreasing
case of TB. [Hoopes et al., 2008]. WHO data reported these regions in the world to have
the following percentage of Isoniazid-resistant TB from their total TB cases from 1994 to
2008: 30% in Eastern Europe, 14% in West/Central Europe, and 14% in Africa [Jenkins et
al., 2011]. National surveys conducted in South Korea for over 20 years revealed an
estimated prevalence of Isoniazid (INH)-resistant TB in 10% of new TB cases and greater
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than 30% in the past treated TB cases [Kim et al., 1992, Bai et al., 2007; Kim et al., 2019].
The treatment outcomes for INH-resistant TB using first-line TB medication were poor.
WHO published meta-analyses and introduced two guidelines on the treatment of INHresistant TB in 2019: 1.) 6 months regimen with Levofloxacin-Pyrazinamide-rifampicinethambutol 2.) no addition of streptomycin or other amikacin, kanamycin, and
capreomycin injectables to the treatment [WHO, 2018].
1. Multidrug resistant tuberculosis
MDR-TB is a type of TB in which the infection is resistant to at least Isoniazid and
rifampicin, the first-line anti-TB drugs. MDR-TB can be treated using second-line TB
treatment; however, the cost of the treatment is expensive (greater than US$ 1000 per
patient), toxic side effects, and the duration of the treatment regimen is long (about two
years) [Falzon et al., 2017]. The global reduction of TB incidence from 2015 to 2019 was
reported to be 9%. Globally, about 465 000 (range, 400 000–535 000) people were reported
with the case of rifampicin-resistant TB (RR-TB), of which 78% of the cases were
estimated to be MDR-TB. The MDR-TB global cases in 2019 are 361,000 [WHO, 2020].
WHO recommended a reduction in the duration of the MDR-TB dosing regimen to 9-12
months [Van Deun et al., 2010; Piubello et al., 2014; Kuaban et al., 2015 Trébucq et al.,
2018; Nunn et al., 2020; Khan et al., 2017, Adidi et al., 2020]. The latest WHO report states
a 57% treatment success rate for MDR-TB treatment globally [WHO, 2020]. A reduction
of 15% occurred for people infected with MDR-TB or rifampicin resistant-TB (RR-TB)
enrolled for treatment from 2019 (177,100) to 2020 (150,359) [WHO, 2021]. According to
a WHO report carried out in 105 countries, 20.1% of average MDR-TB patients were
recorded in 2020 [ WHO, 2020]. World Health Organization (WHO). A total of 206,030
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global cases for MDR-TB/RR-TB in 2019 were diagnosed and reported to WHO and the
national TB programs from 6 WHO countries: Africa (29,155), the Americas (4,979),
Eastern Mediterranean (6,328), Europe (47,936), South-East Asia (86,623), Western
Pacific (31,009) [WHO, 2021]. About 50% of global cases of MDR/RR-TB were in the
following geographical location: Russian Federation (8%), China (14%), and India (27%)
[WHO, 2020].
2. Rifampicin-resistant TB
RR-TB is a subset of MDR-TB. Drug susceptible TB is sensitive to rifampicin treatment,
a potent bactericidal anti-TB due to its effect on penetrating TB bacilli [Lohrasbiet al.,
2018]. The most prevalent mechanism of resistance of Mtb to rifampicin treatment is
through the mutation of the rpoB gene [Gamboa et al.,1998; Kocagoz et al., 2005]. About
465 000 (range, 400 000–535 000) cases were reported globally to develop rifampicinresistant TB (RR-TB) [ WHO, 2021]. WHO has established a list of the high burden
countries for 2021- 2025 for TB cases, HIV- associated TB, and MDR/RR-TB. Thirty
countries were recorded to have a high MDR/RR-TB burden. [WHO, 2021].
3. Extensively drug-resistant tuberculosis (XDR-TB)
WHO revised the definition of XDR-TB in 2021 as 'TB caused by Mtb strains that fulfill
the definition of MDR/RR-TB and which are also resistant to any fluoroquinolone and at
least one Group A drug '[WHO announces updated definitions of extensively drug-resistant
tuberculosis.

https://www.who.int/news/item/27-01-2021-who-announces-updated-

definitions-of-extensively-drug-resistant-tuberculosis]. This new definition was updated in
October 2020 and became applicable from January 2021 [WHO, 2021c].
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WHO also revised the definition of pre-XDR-TB as follows: ‘TB caused by
Mycobacterium tuberculosis (M. tuberculosis) strains that fulfill the definition of
multidrug-resistant and rifampicin-resistant TB (MDR/RR-TB) and which are also
resistant to any fluoroquinolone’. This new definition was updated in October 2020 and
became applicable from January 2021 [ WHO, 2021c].
XDR-TB is a more severe case of MDR-TB with a lower treatment success rate. A total of
12,350 global cases for XDR-TB in 2019 were diagnosed and reported to WHO and the
national TB programs from the 6 WHO countries: Africa (618), the Americas (138),
Eastern Mediterranean (73), Europe (8,560), South-East Asia (2,444), Western Pacific
(517) [ WHO TB global report, 2020]. In 2019 FDA approved a combination of
Pretomanid, bedaquiline, and linezolid to treat XDR-TB cases in specific populations
[FDA news release, 2019]. Previous reports have shown that men are more susceptible to
XDR-TB than women [Flor de Lima et al., 2014]. The strategy to eradicate XDR-TB
stipulates that countries enforce their national TB programs and improve health
practitioners' care of TB patients following the TB care international standards [ WHO,
2014].
4. Totally drug-resistant TB (TDR-TB)
In 2009, a type of drug-resistant TB was termed totally drug-resistant TB (TDR-TB). In
vitro studies showed TDR-TB resistant to first line and second-line TB drugs [Ali et al.,
2009]. The WHO consultative meeting does not recognize TDR-TB due to the difficulty
in the in vitro drug susceptibility testing (DST) and the correlation between DST and
clinical outcome [WHO, 2008]. Some published works reported TDR-TB as XDR-TB or
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XXDR-TB because the approved Bedaquiline and Delamanid may be used to treat TDRTB [Parida et al., 2015]. The cases of TDR-TB are scarcely documented globally; however,
it has been discovered in Italy [Migliori et al., 2007; Parida et al., 2015], Iran [Velayati et
al., 2009], India [Udwadia et al., 2012], South Africa [Klopper et al., 2013].
The emergence of drug-resistant TB incidence globally has renewed the interest in the
global TB discovery and development field. With the appearance of new drug-resistant TB,
the testing and drug therapy for TB patients is becoming progressively difficult. The need
to use potent antibiotics comes with the disadvantages of toxicity, such as
thrombocytopenia, hepatitis, and death. This challenge has motivated the government and
pharmaceutical industries to discover novel anti-TB.
1.7 Global new TB drug pipeline 2021
The pipeline for novel antitubercular drugs as of August 2020 comprises 22 drugs in
clinical trials: phases I, II, and III Figure 7. The drugs include 13 newly discovered
compounds: delpazolid, GSK-3036656, macozinone, sutezolid, SQ109, TBI-223, TBAJ876, TBI-166, BTZ-043, OPC-167832, SPR720, Q203, and TBA-7371. In addition, for
two drugs, delamanid and bedaquiline, regulatory approval was recently accelerated by the
FDA. Levofloxacin, moxifloxacin, clofazimine, linezolid, a high dose of rifapentine, and
rifampicin are six clinically approved antimicrobials currently undergoing testing to
repurpose for TB treatment. Everolimus, auranofin, and CC-11050 (AMG 634). Studies on
novel TB regimens are currently under trial [WHO TB global report, 2020]. Due to the
increase in the MDR-TB, XDR-TB, and TDR-TB globally, the focus has recently been
centered on host-directed therapies as a treatment option [Zumla et al., 2015].
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Figure 7. The global clinical development pipeline for new anti-TB drugs and drug
regimens to treat TB disease [WHO, 2020]. ACTG A5343 DELIBERATE, ACTG
A5312, APT trial, BEAT TB, CLO-FAST trial, endTB, MDR-END, endTB-Q, NeXT,
NiX-TB, ZeNix, SimpliciTB, PredictTB trial, TB-PRACTECAL, STREAM, TBHDT trial,
and TRUNCATE-TB.
Adapted from “The global clinical development pipeline for new anti-TB drugs and drug
regimens to treat TB disease, August 2020” Global tuberculosis report 2020, WHO. (2020),
P. 183. Retrieved from https://www.who.int/publications/i/item/9789240013131
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1.8 Statement of the Thesis Problem
The challenges involved in the treatment of TB includes poor adherence to the current firstline TB regimen [Chan et al., 2002; Munro et al., 2007]. The rise in MDR-TB and XDRTB strains of Mtb has reduced the effect of current treatment options [Fauci et al., 2008;
Cole et al., 1998]. The high cost of treatment of MDR-TB strain is another hurdle in TB
drug treatment [Marks et al., 2014]. In addition, current FDA-approved anti-TB drugs;
pretomanid, bedaquiline, and delamanid, have been discovered to have serious adverse
effects on patients and the cost for procurement of these drugs is expensive. Futhermore,
Mtb strains resistant to the current FDA-approved TB drugs have emerged [Bloemberg et
al., 2015]. In light of the stated challenges in TB therapy, it is, therefore, crucial to discover
promising agents that meet the innovative standard of newly developed antibacterial
agents: A new chemical class, a new mechanism of action, a new drug target, absence of
cross-resistance with existing antibiotics [WHO 2017].
1.9 Specific aims of the Thesis Problem
1. Aim
To characterize OJT008 as a novel antitubercular agent through its inhibition of nickel and
cobalt activated MtMetAP1c enzyme.
Specific Objectives
1. To investigate the in vitro inhibitory effect of OJT008 against nickel and cobalt
activated Mtb Methionine aminopeptidase 1c (MtMetAP1c) using a both genetic
and biochemical approach
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2. To evaluate the inhibitory mechanism of OJT008 against MtMetAP1c using a
computational study approach
3. To investigate the effect of OJT008 against drug-sensitive and multidrug-resistant
type Mtb using a microbiological approach

Figure 8. Specific Aims of the Thesis Problem

CHAPTER 2
LITERARY REVIEW
2.1 TB
TB is an airborne communicable disease, and before the emergence of COVID-19 was the
leading cause of death arising from a single infection globally [WHO Global TB Report
2021]. TB takes about 1-2 years to develop in 5% of its human host after Mtb infection
[Thomas et al., 2003]. A German physician discovered Mycobacterium tuberculosis
complex is the causative organism for an airborne infectious disease called TB [Sakula et
al., 1982; Ryan et al., 2004]. The airborne characteristics of TB were confirmed in the
1950s by Wells and Rile [Riley et al., 1962; Riley et al., 1995]. Although Mtb primarily
infects its host’s pulmonary glands, it is also discovered to affect other parts of the human
body and presents a different spectrum of presentation from asymptomatic to severe cases
of infection [Barry et al., 2009; Esmail et al., 2014]. A continuum exists between the
spectrum of Mtb infection and active TB. Based on public health and clinical perspective,
TB can be categorized into two types: LTBI, which is asymptomatic and noncontagious,
and active TB, which is symptomatic and infectious [Lee, 2016]. TB is one of the major
prevalent infectious diseases, besides HIV/AIDS, Malaria, and recently COVID-19,
globally. 25% of people worldwide are infected with latent TB, and 1.5 million people will
die from TB in 2020. Adults comprise 90% of TB infected people, which
27
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predominantly male globally [WHO 2021]. About 10 million people are ill with active TB
[WHO TB global report 2021]. 5-10% of Mtb infected people develop LTBI within 2-5
years [Anderson et al., 2018]. In both low and middle-income countries, TB remains the
primary factor for mortality and morbidity [Su et al., 2020]. The mode of TB transmission
is through respiratory nuclei droplets from active pulmonary TB infected persons. Such
nucleus droplets contain about 1 to 10 TB Bacilli and can be suspended in the air for hours
before being inhaled into the lungs’ alveoli. About 40,000 droplets are released from a
single sneeze [Cole et al., 1998], and each droplet, no fewer than 10 TB bacilli [Nicas et
al., 2005], can transmit TB disease. The TB bacilli are protected from environmental stress,
dehydration, oxygen, and injury by respiratory secretions surrounding the nuclei droplet,
and the half-life of TB bacilli suspended in the air is about 6 hours [Loudon et al., 1969].
Mtb is not as infectious as other respiratory pathogens like varicella-zoster virus and
measles. A TB infected individual can transmit the infection to 3 to 10 people per annum
[Van Leth et al., 2008]. The virulence of a TB disease results from the infectiousness or
virulence of TB bacilli, bacilli load inhaled, environmental stresses, the strength of host’s
immune system, and other socio-economic factors [Hill et al., 2004]. There are two major
types of TB: active TB disease and latent TB infection. TB infected people are classified
based on the clinical state as either active TB disease or latent TB infection (LTBI). Latent
tuberculosis infection (LTBI) is a type of TB in which the infected person does not manifest
any clinical symptoms, microbiological evidence, and radiological abnormality [Thomas
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et al., 2003]. LTBI is a state of continuous stimulation of Mtb antigens without a clinical
manifestation of active TB [WHO, 2015]. Another type of TB disease is active TB which
arises from the reactivation of subclinical latent TB; therefore, LTBI infected people are a
major reservoir pool of active TB cases [Shea et al., 2014]. LTB refers to a host who is TB
immunoreactive in the absence of TB disease.” [Behr et al., 2021]. TB exists as a dynamic
progression [Young et al., 2008; Barry et al., 2009] from TB infection to active TB disease,
thereby classifying TB into active TB disease and LTBI Figure 9. Infected individuals can
change from one spectrum type of TB to another based on their immunity state and present
comorbidity state. TB exists as a progressive continuum from one end of the spectrum, Mtb
infection, to another end, active TB disease. Exposure of the lungs to Mtb droplets is either
eliminated from the host through its innate or acquired immune system. Expulsion of the
Mtb bacilli through innate immunity without T and B cell priming results in a negative
diagnosis result for both interferon-γ release assay (IGRA) results and tuberculin skin test
(TST). Elimination of Mtb through acquired immunity will result in a positive or negative
IGRA or TST depending on whether T- cells were primed [Barry et al., 2009; Esmail et
al., 2014]. In both previous cases, the people's culture and sputum smear tests are negative,
with no symptoms, noninfectious, and there is no preferred LTBI treatment. Some people
develop a robust memory T cell after eliminating Mtb bacilli are both positive to TST and
IGRA. In the case of LTBI, the bacteria are not eliminated. It remains in a quiescent state
with no clinical manifestation, positive to both TSA and IGRA, noninfectious, negative to
culture, sputum smear, and benefit from LTBI therapy consisting of 6–9 months of
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isoniazid. The subclinical TB type exists in which is the patients are asymptomatic,
infectious, and positive to culture tests [Barry et al., 2009; Dowdy et al., 2013.]

Figure 9. The spectrum of TB — from Mycobacterium tuberculosis infection to active
(pulmonary) TB disease.
Adapted from “Tuberculosis” by Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi,
M., Boehme, C. C., … Raviglione, M. (2016, October 27). Nature Reviews Disease
Primers. Nature Publishing Group. Retrieved from https://doi.org/10.1038/nrdp.2016.76
TB disease occurs when Mtb bacillus is spread from a TB sick person and is spread through
expulsion from the lungs into the air. Mycobacterium is the phylum from the genus
Actinobacteria and the Mycobacteriaceae. About 190 species belong to the genus
Actinobacteria [King et al., 2017]. There are three groups of human pathogenic
Mycobacteria:

Mycobacterium

tuberculosis

complex

(MTC),

Nontuberculous

mycobacteria, and Mycobacterium leprae and M. lepromatosis. Mycobacterium
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tuberculosis complex, which includes Mtb, M. Africanum, M. Carnettii, M. bovis, M.
Mungi. The Nontuberculous mycobacteria are divided into slow and fast-growing
Mycobacteria [Franco-Paredes et al., 2018]. The most clinically important mycobacterium
species infect humans. Mycobacterium bovis is a slow-growing species that affects both
cattle and humans, while another rare Mycobacterium that affects humans in central Africa
is Mycobacterium africanum [Franco-Paredes et al., 2018]. MTC comprises the species M.
africanum, vaccine strain M. bovis BCG (Bacille Calmette-Guérin), M. bovis, M. microti,
Mtb, M. pinnipedii, M. canettii, Mycobacterium orygis, and Mycobacterium suricattae
[Brosch et al., 2002; Huard et al., 2006; Alexander et al., 2010]. These species cause TB in
animals and humans. Most human TB disease is caused by Mtb or a related species,
Mycobacterium africanum. Fewer cases are attributed to M. tuberculosis complex (MTC),
such as Mycobacterium caprae or Mycobacterium bovis [Bos et al., 2014]
Transmission of Mtb infection [ Firdessa et al., 2013] and the reactivation of LTBI [Reed
et al., 2009] are the major causes of TB disease. The genesis of TB disease occurs when
Mtb enters the alveoli sacs and proliferates within the endosome of the host’s macrophages
[Houben et al., 2006; Queval et al., 2017]. Attempts by the host macrophage to
phagocytosis the foreign Mtb bacilli occurs. The bacterium is temporarily stored as a
phagosome by the macrophage, which further forms a phagolysosome. In the
phagolysosome, the white cells attempt to destroy the Mtb cells by utilizing acid and
reactive oxygen species. This attempt by the macrophage is unsuccessful due to the thick
mycolic acid encapsulating Mtb. As a result, Mtb cells reproduce in the macrophage and
eventually destroy the host immune system. The upper action of the lower lobe of the lungs,
known as the Ghon focus, is the focal site for the Mtb infection [Kumar, V., & Robbins, S.
L., 2007]. The upper section of the lungs known as Simon focus can also be infected by
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Mtb [Khan et al., 2011] which is spread through the blood circulatory system. The infection
can also spread to the brain, kidneys, bones, and peripheral lymph nodes [Khan et al.,
2011]. TB is also termed the granulomatous inflammatory disease. An aggregation of B
lymphocytes, T lymphocytes, macrophages, fibroblasts, and epithelioid cells creates the
granulomas, which eventually form large multinucleated cells in the alveolar space. The
granuloma obstructs dissemination of the Mtb infection and fosters interaction between the
pathogen and host immune cells [Jacques et al., 2003]. However, studies have shown Mtb
utilizes granulomas to evade the host's immune system surveillance, thereby suppressing
the host immune system [Bozzano et al., 2014].
The inhaled Mtb droplets evade the protective mechanisms of the bronchi due to the size
of the droplet and enter the alveolar space, where it is counteracted by alveolar
macrophages. Inadequate defense by the alveolar macrophage allows Mtb to invade the
interstitial tissues of the lungs through the infected macrophage migration to the
parenchymatous tissues of the lungs or the Mtb directly infecting the epithelial lining of
the alveolar. Eventually, either infected monocytes [Hoopes et al., 2008] or infected
dendritic cells [Samstein et al., 2013] transfer Mtb to be primed by T cells in the lymph
nodes. Further recruitment of immune cells such as T-cells and B-cells into the parenchyma
of the lungs creates a granuloma. A spectrum of granuloma is found in both latent and
active TB. The proper functioning of the granuloma determines the resultant type of TB
disease [Flynn et al.,2011]. Caseous granuloma is formed in latent TB infection containing
Mtb from spreading. Active TB is formed when the growing bacteria load becomes too
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large for granulomas to contain the pathogen [Lin et al., 2014], allowing Mtb to circulate
through the bloodstream to other parts of the body. This is an infectious stage called the
active TB disease.

Figure 10. Mycobacterium tuberculosis infection.
Adapted from “Tuberculosis” by Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi,
M., Boehme, C. C., … Raviglione, M. (2016, October 27). Nature Reviews Disease
Primers. Nature Publishing Group. Retrieved from https://doi.org/10.1038/nrdp.2016.76

2.2 TB Drug Discovery
The WHO's global TB program collaborates with many research and development
stakeholders and Stop TB partnership groups on novel diagnostics, vaccines, and new
anti-TB to keep track of the development of novel TB tools. Progress and setbacks in the
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research and development of TB tools are recorded annually in the "Global tuberculosis
report.” The objective of anti-TB discovery is to develop new TB drug regimens and TB
drug discovery that are more efficacious, potent, safe, and accessible to all patient
populations [Mdluli et al., 2015]. The commercial viability for anti-TB drugs is low;
therefore, the focus in this area is minimal. Providentially, non-government and
government organizations have taken steps to correct the situation by creating programs
such as the Global Alliance for TB Drug Development (TB Alliance). TB Alliance forms
a unification of governments, non-government organizations, industries, and an estimated
30 partners around the globe to fast-track the discovery and development of cost-effective
antitubercular drugs [Global Alliance for TB Drug Development (TB Alliance) Active
Since 2000]. Various consortia have been developed, including Orchid, the Lilly Early
TB Drug Discovery Initiative, More Medicines for TB (MM4TB), anti-TB Drug
Accelerator. The Gates Foundation and the National Institutes of Health (NIH), funded
by the government and academic laboratories, are also involved in translational research
to discover TB drugs. Bedaquiline was approved by FDA on 28 December 2012 [US
Food and Drug Administration (FDA), 2012; Mahajan et al., 2013], and delamanid was
approved in December 2013 by the European Medicines Agency and the Japanese
regulatory authorities [European Medicines Agency, 2014]. Both drugs are recommended
for MDR-TB drug therapy. Current drug discovery studies have not provided sufficient
hit-lead generation to develop antimycobacterial, which shortens TB therapy duration,
reduces the TB drug regimen, and ultimately changes the paradigm of TB treatment. The
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efficient utilization of current molecular biology in whole-genome sequencing of Mtb
genes since 1998 [Cole et al., 1998] has accelerated the progress in TB drug discovery.
Essential Mtb genes in vitro and in vivo [Sassetti et al., 2003], genome-wide DNA
microarrays study to elucidate specific gene expression under different conditions
[Sherman et al., 2001; Schnappinger et al., 2003; Zhang et al., 2012], and the determination
of novel drug targets by elucidating mutated genes in drug-resistant mutants [ Abrahams
et al., 2012; Loerger et al., 2013] were discovered through the knowledge of Mtb whole
genome. Deleting specific genes through the molecular technique of gene knockdown has
helped in vitro and in vivo validation of novel drug targets [Park et al., 2011].
2.2.1 Repurposed drug candidates for TB treatment
Drug therapy for TB has been adopted for eradicating TB infection for the past 70 years;
however, the duration of the antimycobacterial regimen constitutes TB drug resistance
emergence. Over the years, the impediment in TB therapy due to drug-resistant Mtb strains
has posed severe public and health challenges. The strategy of repurposing existing
clinically approved antibiotics for treating TB disease circumvents the bottlenecks in antiTB drug development. Repurposing existing drugs for TB treatment is a promising strategy
for eradicating both TB diseases and drug-resistant TB infections. The strategy of
repurposing existing clinically approved antibiotics for TB disease treatment reduces the
bottlenecks in anti-TB drug development. Novel compounds such as delamanid,
bedaquiline, and pretomanid have been discovered to improve the therapeutic outcome of
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MDR-TB and XDR-TB [Mahajan, 2013; Ferlazzo et al., 2018]. However, clinical failure
has already been discovered in TB therapy [Olayanju et al., 2018]. Repurposing existing
drugs has the advantage of being cost-effective and a shorter time of approval for human
consumption. Another merit of this approach is that existing lead compounds can be
modified through structural modification or computer-based design with a high-throughput
approach [Pushpakom et al., 2018]. The following are repurposed drug candidates
currently investigated for TB drug therapy.
1. Nonsteroidal anti-inflammatory drugs
Ebselen and Diminazene aceturate are both Nonsteroidal anti-inflammatory drugs being
repurposed for TB treatment. Diminazene are indicated for trypanosomiasis and babesiosis
[Da Silva Oliveira et al., 2015]. Cappoen et al. performed an anti TB activity screen of 26
compounds with a 1,3-diaryltriazenes structure. These compounds were structurally
modified to obtain three lead analogs with a potential for antitubercular activity [Cappoen
et al., 2014]. Ebselen is indicated for cytoprotective, anti-atherosclerotic, antiinflammatory, and antioxidant properties [Scheweet al., 1995]. Padiadpu et al., through a
combination of whole-genome sequencing and phenotypic profiling, discovered isoniazid
and ebselen, among which are potent against Mtb H37Rv and three other strains resistant
to drug therapy, MYC431, JAL2287, and BND3200 [Padiadpu et al., 2016].
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2. Antimalarial
Artemisinin is an antimalarial extract from the Chinese shrub Artemisia annua. Together
with Its derivative, Artesunate has been proven to have potent antimalarial activity and
more pharmacological properties [White et al., 1997]. Choi et al. postulated the
effectiveness of artemisinin in blocking or modulating the proliferation of Mtb. This
hypothesis was investigated and confirmed by using several anti-TB indicator assays,
thereby proving the efficacy of artemisinin has a potent effect against Mtb activity [Choi
et al., 2017]. Chloroquine is a known antimalarial drug [Baruah et al., 2018]. Clearance of
isoniazid by efflux pump, breast cancer resistance protein-1, is inhibited by chloroquine,
therefore increasing the potency of standard antitubercular drugs [Matt et al., 2017]. The
mechanism of chloroquine in inhibiting phagosomal acidification increases the
susceptibility of drug-sensitive Mtb to drug treatment, decreases post-drug treatment
relapse in the BALB/c mouse model, and alleviates lung pathology after TB infection.
Chloroquine reduces the duration of TB treatment and increases the efficacy of anti -TB
[Mishra et al., 2019]. Bermudez et al. 2014 discovered Mefloquine has a potent bactericidal
effect against Erdman and Mtb H37Rv strains in unfavorable conditions and in
macrophages [Bermudez et al., 2014]. Mefloquine and oxazolidine-derivative compounds
were discovered by Rodrigues et al. in 2016 to be active in TB infected murine model
[Rodrigues-Junior et al., 2016]
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3. Antibiotics
In vitro studies by Kaushik et al. discovered the potency of Biapenem, a drug candidate
under trial for treating pseudomonas aeruginosa [Chen et al., 1994], and Tebipenem, a
drug indicated for respiratory tract infections [Sato et al., 2008 ] against drug-susceptible
Mtb H37Rv with a minimum inhibitory concentration ( MIC90) of 2.5 - 5 µg/mL
[Kaushik et al., 2015] and 1.25- 2.5 µg/mL [Kaushik et al., 2015] respectively with a
reported 4-fold reduction of minimum Inhibitory Concentration (MIC) values for both
carbapenems with the addition of clavulanate. In vivo Study by Kumar et al. [Kumar et
al., 2017] also determined the potency of biapenem, or in combination with rifampicin, in
Mtb infected BALB/c mice. They discovered the biapenem reduced the lesion in the
lungs of the infected mice at a 90% minimum inhibitory concentration (MIC90) by
inhibiting nitrocefin hydrolysis by the activity of L, D-transpeptidase, and LdtMt2 [Guo
et al., 2019; [Kumar et al., 2017]. An in vivo study by Kumar et al. also showed that
Tebipenem inhibited LdtMt1 and LdtMt2 hydrolysis of nitrocefin [Guo et al., 2019].
4. Antiviral drugs
Isoprinosine is indicated for treating subacute sclerosing panencephalitis [CampoliRichards et al., 1986]. The antiviral drug stimulates cytokine, thereby playing an important
function in the Mtb host immune resistance. Mishra et al. hypothesized Isoprinosine's
immunostimulatory effect warrants the use of the drug as a prophylactic for TB treatment
[Mishra et al.,2018].
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5. Cardiovascular drugs
Verapamil is a selective calcium channel blocker clinically approved for managing
hypertension, angina, and arrhythmia. It inhibits the P-glycoprotein transporter, thereby
modulating the absorption of drugs into cancer cells. As such, it is used in combination
with antineoplastics to prevent resistance to cancer drugs. It is hypothesized that
alteration of membrane efflux pump would reduce the viability of intracellular
functioning Mtb. Verapamil, therefore, can inhibit the viability of Mtb intracellularly and
boost the efficacy of other anti-TB when combined [Adams et al., 2011; Adams et al.,
2014]. In vivo studies have demonstrated the efficacy of the combination of verapamil
and rifampicin treatment increases the potency of other antitubercular drugs [Canezin et
al., 2018]. Ghajav et al. study also further validated the efficacy of verapamil in reducing
certain strains of Mtb efflux pump [Ghajavand et al., 2019].
Simvastatin is a coenzyme A reductase inhibitor indicated for lowering cholesterol levels
and management of hypercholesterolemia [Atil et al., 2016]. Skerry et al. postulated that
simvastatin could increase the immune response of macrophages, thereby boosting the
efficacy of standard anti-TB agents. They discovered that 5µM of simvastatin could
enhance the activity of isoniazid in J774 macrophage-like cells. In addition, the group in
an in vivo study discovered that the advantage of a combinatorial regimen with simvastatin
was more effective than rifampicin, isoniazid, or pyrazinamide alone, in killing the Mtb
bacilli load with a resultant decrease in the colony-forming units, in Mtb infected BALB/c
mice [Skerry et al., 2014]. A Series of studies by Dutta et al. in 2019 strongly point to
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Pravastatin as an effective adjunctive host-directed therapy for TB disease [Duttaet al.,
2020]

6. Anticancer drugs
In 2003 FDA approved bortezomib, a proteasome inhibitor, for the treatment of Multiple
myeloma [Dou et al., 2014]. A new antimycobacterial screening protocol, which involves
both whole-cell and target approach methods, was developed by Moreira et al [Moreira et
al., 2015]. Bortezomib was discovered to have potent activity against Mtb and M.
smegmatis through the mechanism of inhibiting caseinolytic protease. The poor
pharmacokinetic profile, cost, and prominent adverse effects have limited the utilization of
bortezomib for TB therapy [ Wilfred et al., 2017]. Gorovoy et al. discovered analogs of
boron-containing peptidomimetic compound, with scaffolds identical to bortezomib, to be
potent against Mtb with a MIC value of <5 µg/mL [Gorovoy et al., 2013]. Elesclomol is an
anticancer drug that induces apoptotic cell death of tumor cells through oxidative stress
[Kirshner et al., 2008]. Ngwane et al. carried out an in vitro anti-TB activity assay for
Elesclomol against Mtb H37rv and discovered an IC50 of 4µg/mL. They also discovered
the drug to be potent against bone marrow macrophages infected with active Mtb by using
a checkerboard assay [Ngwane et al., 2019]. Another strategy for combating TB
proliferation in infected cells is by an effective modulation of the host's immune response.
Metformin is a drug indicated for Type 2 diabetes and hypoglycemia. Metformin directly
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inhibits adenosine monophosphate-activated protein kinase (AMPK) and mammalian
target of rapamycin (mTOR) which modulates autophagy [Liu et al., 2014]. Singhal et al.
2014 discovered metformin increases AMPK and blocks MDR-Mtb, and M. tuberculosis
H37Rv strains in human monocyte-derived macrophages and THP-1. In an in vivo TB
infected mouse model, using just metformin or combined with ethionamide or isoniazid
reduces inflammation, improves immune function, and alleviates lung pathology. These
results further support the hypothesis of using metformin to modulate the host immune
system to enhance the effectiveness of drug-resistant TB therapy [Singhal et al., 2014].
Currently, several studies are being conducted to determine the safety and efficacy of
metformin for treating Mtb infection [Lachmandas et al., 2019; Park et al., 2019]. Another
antidiabetic agent under investigation for TB treatment repurposing purposes includes Bisbiguanide dihydrochloride [Shen et al., 2016]. Other drugs also studied for repurposing for
TB treatment include rimonabant, an endocannabinoid receptor antagonist indicated for
treating obesity [Fong et al.,2009], and Ramesh et al. studies show the effectiveness in
inhibiting Mtb H37Rv [Ramesh et al., 2016]. The major limitation in the repurposing drug
candidates for TB treatment is that the potency of existing candidates against TB is low,
and fewer drug candidates available for repurposing purposes.
2.3 Approaches to Antitubercular drug discovery
The burden of TB disease and the emergence of MDR-TB and XDR-TB strains have posed
challenges to the efficacy of existing anti-TB drugs hence the urgency to discover novel
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drugs to add to the current treatment strategy. Both traditional and innovative approaches
are being adopted in the discovery of novel anti-TB drugs [Migliori et al., 2020]. There are
two major approaches to anti-TB drug discovery> target-based approach, and the whole
cell-based approach recently added to the methods is the target mechanism-based wholecell screening.
Currently, 23 drug candidates are in the TB drug discovery pipeline with studies on
effective anti-TB combination regimens for treating drug-susceptible, XDR-TB, and XDRTB strains [WHO global TB report, 2020]. It is essential to discover novel drug candidates
that require a lesser duration of treatment (the least duration for current TB treatment is six
months), are affordable, safe, and will pose no drug-drug adverse interaction when coadministered with current antitubercular drugs [WHO global TB report, 2020]. The major
challenges in the rate of discovering drug candidates against Mtb are primarily due to the
slow-growing nature of the pathogen, existing in different growth phases [Smith et al.,
2013; Gomez et al., 2015], and existence in granulomas and macrophages [Hussain Bhat
et al., 2015].
2.3.1 Target-based approach for the discovery of novel TB drugs
This approach is also termed 'reverse pharmacology.' It is an HTS of studied molecular
targets to determine drug candidates that inhibit or induce the target. In some cases, the
knowledge of the molecular targets can also be understood by the phenotypic approach to
drug discovery [Lage et al., 2018]. Genomic and recombinant technology is utilized in the
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Target-based drug discovery approach. The whole Mtb genome sequencing expedited the
discovery of novel Mtb drug targets. It starts with the knowledge of the drug target and
ends with the discovering an effective drug candidate that efficiently inhibits the molecular
target. The knowledge of a molecular target avails the utilization of mutational analysis
and computational modeling to determine the interaction of drug candidates with the target.
Despite the challenges characterized by this approach, it remains a critical aspect of
determining if drug candidates can be translated to the preclinical phase of drug study
[Hughes et al., 2011]. The classic TB targets for drug discovery are peptides and proteins
expressed in critical biological pathways essential for Mtb viability, these proteins are
absent in humans, or the nucleotide sequence of the Mtb protein is less identical to the
human homolog. Several Mtb enzymes hypothesized to be promising targets for TB drug
candidates based on the essentiality of these enzymes for the viability of Mtb are currently
under investigation. Examples of these targets are Enoyl-acyl carrier protein reductase
[Shirude et al., 2013; Sullivan et al., 2016], N-Acetylglucosamine-1-phosphate
uridyltransferase [Li et al., 2011; Rani et al., 2015], Decaprenylphosphoryl-D-ribose 20epimerase [Batt et al., 2012], Maltosyltransferase GlgE [Veleti et al., 2014], Pantothenate
synthetase [Samala et al., 2013], and methionine aminopeptidase 1 [Olaleye et al., 2010;
Olaleye et al., 2011; John et al., 2016]
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2.3.2 Phenotypic based approach for the discovery of novel TB drug
This is also called whole-cell screens, and the approach involves administering a compound
or drug candidate to a cell or pathogen and observing the effect or phenotypic change of
the organism after treatment. The phenotypic-based approach is a fast way to determine
Mtb inhibitors [Ballel et al., 2013; Rebollo-Lopez et al., 2015] by utilizing thousands of
drug and compound candidates from libraries unearthed from high-throughput screens
(HTS) [Ananthan et al., 2009]. This approach paves the way for the discovery of anti-TB
drugs that inhibit both Mtb pathways and targets. This approach circumvents the challenges
arising from the permeability of drug candidates into cell membranes and has the added
advantage of determining the cytotoxicity of screened compounds. In the past, most
documented research on whole-cell screens was carried out in aerobic culture conditions,
which are favorable for replication of Mtb strain. Recently innovative phenotypic drug
screens have been designed to simulate the in vivo condition of host cells infected with
Mtb, for example, the screen of Mtb infected macrophages [Christophe et al., 2010]. This
approach is relevant in discovering drug candidates that are potent against persisters.
However, the lack of knowledge of the specific drug target of the bacteria poses a limitation
of this method. Whole-genome sequencing of Mtb in 1998 has led to a promising outlook
in the target-based screen approach [Mayer., & Hamilton, 2010]. The phenotypic high
throughput screen of libraries of TB drug candidates aided the discovery of pretomanid
[Stover et al., 2000], bedaquiline [Protopopova et al., 2005], Q203 [Pethe et al., 2013], and
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delamanid [Matsumpoto et al., 2006] which are under clinical trial [WHO TB global report,
2020]. An aspect of this dissertation project involves the phenotypic-based approach.
Another approach recently adopted is the target mechanism-based whole-cell screening. In
the past, the discovery of antibacterial agents adopted the biochemical assay methods to
investigate the interaction of novel pharmacophores recombinant purified protein, and less
focus was on the whole-cell approach. This approach has not been quite productive in
discovering antibacterial compounds that the inhibitory effect can be translated into
potency against whole-cell models. These challenges are major because of the permeability
of the poor compound to the cell membrane. This has prompted studies to be shifted to the
whole-cell approach method. However, this method's main limitation is the lack of
knowledge of the cellular target before the drug screen. Another novel approach called the
target mechanism-based whole-cell screening is a synergy of both approaches: target-based
and whole cell-based, which maximizes the merits of both approaches. Moreira et al.
[Moreira et al., 2017] adopted this method by repurposing the clinically approved
bortezomib for Mtb therapy
2.4 Methionine aminopeptidase; a promising chemotherapeutic target
Methionine aminopeptidases (MetAP) is a universal enzyme essential for the viability of
Mtb [Olaleye et al., 2010]. The protease is a dinuclear metalloprotease that catalyzes the
excision of N-terminal methionine (NME) from nascent proteins from the ribosome during
protein translation [Lowther & Matthews, 2000; Giglione et al., 2003; Olaleye et al., 2009].
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NME is required for subcellular localization, protein-protein interaction, stability, and
protein degradation of some proteins [Giglione et al., 2004; Krishna et al., 1983].
The biological function of MetAP in Mtb was identified by Olaleye, Ph.D., MSc, through
a combination of genetic and chemical approaches. MetAP was reported to be essential in
Salmonella typhimurium [Miller et al., 1989], Escherichia coli (E. coli) [Chang et al.,
1989], and yeast Saccharomyces cerevisiae [Chang et al., 1992; Li, X., & Chang et al.,
1995]. In the NME pathway, MetAP removes the N-terminal methionine from nascent
proteins after the activity of Peptide deformylase (PDF) [Giglione et al., 2004, Lowther.,
& Matthews,2000]. NME occurs in 55-70% of nascent proteins [Giglione et al., 2004].
PDF was initially reasoned to be a promising drug target; however, the essentiality of PDF
was refuted due to the ability of organisms to mutate the formyltransferase gene [Solbiati
et al., 1999, Mazel et al., 2004]. The critical function of MetAP in all life forms has made
it a promising target for discovering novel antibacterial agents, including drug-resistant TB
[Vaughan et al., 2012, Olaleye et al., 2010]. MetAP has been discovered as an attractive
target for the discovery of drugs for the treatment of diseases such as cancer, rheumatoid
arthritis, parasitic and fungal infections [Griffith et al., 1997; Sin et al., 1997; Zhang et al.,
2002; Bernier et al., 2004; Han et al., 2018; Rodriguez et al., 2020]. MetAP exists in 2
types, MetAP1 and MetAP2, and are differentiated by inserted polypeptide located in the
catalytic domain of MetAP2 [Arfin et al., 1985]. MetAP1 exists as four isoforms:
MetAP1a, MetAP1b [Addlagatta et al., 2005], [Giglione et al., 2000], MetAP1c, MetAP1d
[Chen et al., 2006], and MtMetAP1n, [Bala et al., 2019]. MetAP1b and MetAP1c are
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distinguished from MetAP1a by the presence of N-terminal extension in the subtypes. Xray structures of apo and holo form of MetAP1c revealed conserved proline residues in the
N- terminal extension, which is absent in MetAP1a [Addlagatta et al., 2005]. The biological
role of MetAP in bacteria shows the enzyme as a promising drug target.

2.4.1 Mtb Methionine aminopeptidase (MtMetAP)
Mtb differs from most prokaryotes in possessing two isoforms of Mycobacterium
tuberculosis methionine aminopeptidase (MtMetAP1); MtMetAP1a and MtMetAP1c,
which both share 33% identity [Sherman et al., 1985] but differs by the presence of 40
amino acid residues in the N-terminal of MtMetAP1c which is relevant for ribosomal
interaction [Addlagatta et al., 2005].
Olaleye et al. generated both MtMetAP1a and MtMetAP1c and performed a target
validation study to determine to function of MtMetAP1s in Mtb [Olaleye et al., 2010].
They discovered MtMetAP1a is essential for the viability of Mtb. The mutated type of
MtMetAP1a phenotypically manifested slow growth of Mtb. The result signified
MtMetAP1a as a promising chemotherapeutic target for Mtb treatment [Olaleye et al.,
2010]. A previous transcriptional comparative analysis study by Zhang et al. showed a
difference in the transcript level of mapA (MtMetAP1a) and mapB (MtMetAP1c) transcript
level during the exponential and stationary expression level in Escherichia coli (e. coli)
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culture. They suggested the biological role of the enzymes in the growth phases of Mtb
[Zhang et al., 2009]. mapA was expressed more in the log phase while mapB's expression
level was higher in the stationary phase, thereby suggesting the different roles of
MtMetAP1a and MtMetAP1c in the growth phase of Mtb [Zhang et al., 2009]. The
transcriptional level of mapA was comparatively higher in the stationary phase compared
to the bacteria culture's log phase. mapB transcript level was discovered to be higher in the
log phase in comparison to the log phase. The results suggest the different roles of
mtMetAP1a and MtMetAP1c in the growth phase of Mtb [Zhang et al., 2009]. Olaleye et
al. utilized both target-based and phenotypic drug discovery approaches to discover TB
drug candidates. This was achieved by utilizing a chromogenic substrate enzymatic assay
adapted from Zhou et al. [Zhou et al., 2000] to study the effect of a library of compounds
against both MtMetAP1a and MtMetAP1c and discovered promising lead compounds
[Olaleye et al., 2010, 2011, 2012, 2016].
2.4.2 MtMetAP: a dinuclear metalloprotease
MetAP, a dinuclear metalloprotease, and divalent metal ions directly participate in the
removal of N-terminal methionine from nascent polypeptides by MetAP. The NME
process is activated by divalent metal ions such as Ni2+, Fe

2+

, Co2+, Mn2+, and Zn2+ [D'

Souza et al., 2007; Lowther et al., 2009]. The proteolytic activity of MetAP is inhibited by
Ethylenediaminetetraacetic acid (EDTA), further validating the metalloprotease nature of
MetAP [Arie et al., 1987]. MetAP1 proteins are activated by cobalt or zinc metals for their
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activity [ Arfin et al., 1985]. MetAP utilizes conserved amino acid residues to create a
scaffold having the capacity to bind at most two metal ions [Lowther et al., 2002]. E.coli
MetAP was discovered to be activated by Mn(II), Ni(II), Fe(II), Zn(II),and Co(II) [D’
Souza et al., 2007]. MetAPs are metalloproteases that are activated by the following
divalent metals, Mn (II), Co (II), and Fe (II) as cofactors to activate their inherent catalytic
activity [Zhang et al., 2009; Olaleye et al., 2010; John et al., 2016]. The metal required for
the activity of MtMetAP1 in its native physiological form has been a subject of debate.
A supplemental work by Olaleye et al. [Olaleye et al., 2010] in which the metal: cobalt
(Co) and manganese (Mn), the dependence of apo of MtMetAP1a and MtMetAP1c screen
were conducted. MtMetAP1 was discovered to be dependent on both metals for their
inherent activity in a concentration-dependent manner. In this dissertation work. We
conducted preliminary work to investigate the dependence of the holo from MtMetAP1c
on Nickel and cobalt.
2.4.3 MtMetAP1c essential for the viability of Mtb
The essential nature of both MtMetAP1a and MtMetAP1c have been studied by different
research groups. Investigations of promising MetAP1 inhibitors for Mtb metalloprotease
have been conducted over the years. Olaleye et al. adopted both genetic and chemical
approaches in determining the essentiality of either MtMetAP1a or MtMetAP1c in Mtb
growth [Olaleye et al., 2010]. Overexpression of either isoform conferred resistance of Mtb
to screened inhibitors, and knockdown of the MtMetAP1a gene decreased the growth of
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Mtb. However, the viability of Mtb growth is moderately affected by the knockdown of
mapB, suggesting its nonessential role in Mtb [Olaleye et al., 2010]. Additional studies
have proven the importance of MtMetAP1c in Mtb viability. Results from a Transcriptional
comparative analysis by Xuelian Zhang et al. [Zhang et al., 2009] showed the mapA and
mapB transcripts are expressed more in the exponential and lag phase, respectively, in an
E.coli growth. These findings suggest the different roles both genes play in the viability of
Mtb. The life cycle of Mtb may very well require more than one MtMetAP1 to catalysis
the co-translational modification. A comparative genomic study of the roles of genes in
Mtb species by Ribeiro-Guimarães et al. showed that both MtMetAP1a and MtMetAP1c
are essential for the survival and pathogenicity of Mtb [Ribeiro-Guimarães et al., 2007].
The findings of Miriam et al. suggested the essential role of mapB for Mtb viability
[Vanunu et al., 2019]. Furthermore, studies have shown that MtMetAP1c displayed activity
in a wider pH range compared to MtMetAP1a, having about 60% of its activity intact at a
pH as low as 6.5. This characteristic suggests the role of MtMetAP1c in Mtb in an acidic
condition such as in the host macrophage
A high-density transposon-mutant library analysis by Christopher et al. suggested mapB as
essential for Mtb growth and survival [Griffin et al., 2011]. In this dissertation project, we
endeavored to characterize OJT008 activity against MtMetAP1c based on the viability of
Mtb by MtMetAP1c from a literature review.
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2.4.4 Essentiality of divalent metal ions for MtMetAP1 activity and discovery of Mtb
MtMetAP1 inhibitors
A study by Zhang et al. showed MtMetAP1c catalysis is increased magnesium (II) ion,
Manganese (II) ion, Cobalt (II) ion, and zinc (II) ion. They discovered that the activity of
the enzyme is reduced by Ni2+, Cu2+, Fe2+. Zhuang et al. discovered the different binding
affinities of various inhibitors against MetAPs activated by various metals [Ye et al., 2003;
Ye et al., 2004]. Nickel, on the other hand, is known to be an excellent MtMetAP1c
cofactor [Lu et al., 2010]. Zhang’s study used metallated enzymes, not in its apoenzyme;
therefore, the inhibitory effect of Ni2+, Cu2+, Fe2+ was probably due to competition of the
metal added with the active site metal already in place. In silico approach in the drug
discovery approach, discovered compounds have varying binding affinities to MetAP with
different metals at the active site [ Wang et al., 2003; Zhuang et al., 2004]. The two types
of MyMetAP1 are activated by Fe 2+, Ni 2+, Co 2+, and Fe2+for its NME activity Fe2+ [Lu.,
& Ye., et al., 2010a], Zhuang et al., 2010]. Current MetAP inhibitors were characterized
using MetAP in its Co2+form. However, recently discovered MetAP1 inhibitors, albeit
potent against in vitro bacterial MetAPs, displayed a less significant potency against the
corresponding bacterial activities [Luo et al.,2003; Douangamath et al., 2004]. It was
discovered that inhibitors of Co2+ forms of MetAP1 might not effectively block the activity
of different metal-activated MetAP [ Li et al., 2003; Qi-Zhuang et al., 2004]. Cobalt (Co2+)
Co (II) are exceptional activators of apo-form MetAPs. Recent MetAP inhibitors were
discovered by screening against Co2+ activated MetAPs [Oefner et al., 2003; Luo et al.,
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2003; Huang et al., 2007]. The challenge of the discrepancy between the in vitro and in
vivo potency of MetAP inhibitors can be because of the difference in the affinity of the
MetAP and MtMetAP1 for specific metals in vitro and their native cellular state. The
challenge in designing a potent, selective inhibitor of pathogen MetAPs is in discovering
the specific divalent metals in the active sites of the metalloproteases.
Several studies have focused on elucidating the inhibitory effect of MetAP1 inhibitors
against the enzyme activated by different metals to optimize IC50 value [ Huang et al.,
2007], [Lu et al., 2010], [ Lu et al., 2011], [Juhás et al., 2022] and [Lu et al., 2012]. Jing
Ping et al. discovered Nickel as an excellent activator of MtMetAP1c activity [ Lu et al.,
2010b] discovered 1,2,4-Triazole Based Inhibitors inhibit the activity of MtMetAP1 by
chelating Ni2+ at the active site of MtMetAP. Aryl Carboxylic Acid Inhibitors were
discovered to bind specifically to the Mn2+at the active site of E. coli MetAP1 [D' Souza et
al., 2007]. Therefore, the knowledge of the specific metal(s) in the active site of
MtMetAP1, which OJT008 has a high binding affinity as investigated by both in vitro and
in silico studies, is important.
2.5 OJT008, a MetAP1 inhibitor
OJT008 is a compound purchased from MolPort, Inc. The IUPAC name for the compound
is

N-benzyl-5-chloro-N,6-dimethyl-2-pyridin-2-ylpyrimidin-4-amine,

PubChem

Compound CID: 2740173. The compound's protein target stated in the PubChem source is
the Metalloprotease M24A subfamily of protease inhibitors. M24A is the family of
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methionyl aminopeptidase, one from E.coli, metallopeptidase families, that requires cobalt
or manganese for its catalytic activity [Neil et al., 2013]. Olaleye et al. screened 175,000
compounds from ASDI Inc. in Johns Hopkins University, against MtMetAP1c at a final
concentration of 30 µM. They selected 439 compounds based on a 30-40% inhibition of
MtMetAP1c. 81 MetAP1 compounds were discovered by Olaleye et al. which were also
potent inhibitors of MtMetAP1s at 10 µM, and 21 of the structural analog’s hits were
further selected based on their potency against Mtb. OJT008 was selected from the analogs
[Olaleye et al., 2010], and the compound was discovered and patented by Olaleye et al. as
a Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases. Methionine
Aminopeptidase Inhibitors for Treating Infectious Diseases

Figure 11. 2-D Structure of 0JT008
Adapted from PubChem, National Library of Medicine. Retrieved from
[https://pubchem.ncbi.nlm.nih.gov/compound/2740173]
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In another study, Olaleye et al. screened eight compounds, OJT001- OJT008, to investigate
their antileishmanial in vitro effect. OJT006, OJT007, and OJT008, which were discovered
to be potent against Leishmania major (L. major) promastigotes and amastigotes infected
macrophage cells. OJT008 was previously discovered as a promising chemotherapeutic
candidate against cutaneous leishmaniasis infection caused by L. major infection by
inhibiting the enzyme methionine aminopeptidase1 of Leishmania major. The compound
was a potent inhibitor of methionine aminopeptidase 1 of L. major in both In vitro and In
vivo studies. The study also showed the compound is nontoxic to intraperitoneal murine
macrophages, which suggests the safety level of the compound [Rodriguez et al., 2020]. In
this dissertation project, we sought to characterize OJT008 as a novel inhibitor of Mtb by
determining the effect against metal-activated MtMetAP1c and potency against both drugsensitive-Mtb and MDR-TB strains of Mtb. We further performed an in silico study to
further investigate the molecular interaction and binding score of OJT008 to both metalactivated MtMetAP1c. Our study validated the pharmacophore’s metal specificity.

CHAPTER 3
DESIGN OF THE STUDY
Our study is focused on characterizing the effect of OJT008 against MtMetAP1c and Mtb
culture. To achieve this objective, we cloned the target gene, cultured and overexpressed
the target protein, purified it to near homogeneity, and the effect of OJT008 against metal
activated MtMetAP1c activity was determined. An in silico study was conducted to
investigate the binding characteristics of OJT008 to the divalent metals at the active site of
the metalloprotease. We collaborated with Houston Methodist to screen the potency of our
compound against both drug-sensitive Mtb and MDR- Mtb strains. We adopted the genetic
cloning technique, molecular technique, biochemical enzymatic assay, computational
study, and microbiological approach in this study.
Materials required:
Polymerase chain reaction (PCR) Machine (PTC-200 Peltier Thermal Cycler),
Deoxynucleoside triphosphates (dNTPs): dATP, dCTP, dGTP, and dTTP, Taq polymerase
from New England Biolabs ®, Genomic DNA from Mycobacterium tuberculosis strain
H37Rv from ATCC catalog # 25618D-2™, Lot number: 70012901, 10x standard Taq
reaction buffer, forward primer: 5’-GCGGGATCCCCTAGTCGTACCGCGCTC-3’
(Batch number: WD08128249), reverse primer
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5’-GCGTCGAGCTACAGACAGGTCAGGATC-3’ (Batch

number:

WD08128250)

purchased from Sigma-Aldrich®, pET-28a(+) DNA purchased from Novagen (catalog
number: 69864-3, Lot number: 3228343, BamHI and XhoI restriction enzyme purchased
from Invitrogen®, (6X) Gel Loading Dye purchase from NEB (catalog # B7024S), T4
DNA Ligase Buffer (catalog# M0202S) purchased from NEB, L-Methionine para
nitroanilide purchased from sigma Aldrich, CAS Number: 6042-04-2, the Qiagen Plasmid
Plus Midi Kit from Qiagen inc, HisPur™ Ni-NTA Resin and isopropyl beta-Dthiogalactopyranoside (IPTG) were purchased from Thermo Fisher Scientific®,
Subcloning Efficiency™ DH5α Competent Cells Catalog number: 18265017 purchased
from Invitrogen®, One Shot™ BL21 Star™ (DE3) Chemically Competent E. coli, Catalog
number: C600003, purchased from Thermofisher scientific, Middlebrook 7H9 broth, a Mtb
cultures medium (purchased from Becton Dickinson). OJT008 compound was purchased
from Molport® and were prepared in Dimethyl sulfoxide (DMSO) purchased from Sigma
Aldrich. Below is the flow chart of my study design.
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Figure 12: Flow chart of study design

58

3.1 Cloning and overexpression of MtMetAP1c

Figure 13. Outline for cloning and overexpression of MtMetAP1c
3.1.1 Amplification of MtMetAP1c gene from Mtb H37Rv genome
The study accomplished the aim of cloning, overexpressing, and purifying the expressed
recombinant target protein, MtMetAP1c, with the N-terminal end of the sequence tagged
with the 6x poly-histidine. The overexpression of MtMetAP1c was achieved by
constructing a recombinant pET28a- MtMetAP1c using ligation technique. The amplified
DNA produced a prominent band corresponding to the 858bp for MtMetAP1c,
corresponding to the 1 kb DNA marker on agarose gel. The protocol was adapted from
‘PCR Protocol for Taq DNA Polymerase with Standard Taq Buffer (M0273)- New
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England Biolab’ (https://www.neb.com/protocols/0001/01/01/taq-dna-polymerase-withstandard-taq-buffer-m0273). MtMetAP1c was polymerase chain reaction amplified from
the genomic DNA of Mtb H37Rv using the forward and reverse primers;
5’-GCGGGATCCCCTAGTCGTACCGCGCTC-3’
and 5’-GCGTCGAGCTACAGACAGGTCAGGATC-3’ respectively. .To prepare a 50µL
PCR reaction, the following was prepared by adding the following to the PCR tube to first
prepare a 3x mix. 47.625µL of autoclaved water, 7.5 µL (10x)10x Standard taq reaction
buffer, 1.5µL of 10mM dNTPs, 1.5µL for both forward and reverse primers, and 0.375 µL
of taq DNA polymerase. The mixture is briefly mixed, 20µL of the mix is aliquoted, and 5
µL (500 ng) of the Mtb strain H37Rv genome DNA.
Table 3. PCR Reaction setup.
Component
10x Standard taq reaction buffer
10mM dNTPs

50µL reaction
3 x 2.5

Final concentration
1x

3 x 0.5

200 µM

10 µM Forward Primer

3 x 0.5

0.2 µM

10 µM Reverse Primer

3 x 0.5

0.2 µM

Taq DNA Polymerase

3 x 0.125

0.325 units

Nuclease-free water

to 50 µL

to 50 µL

Adapted from PCR Protocol for Taq DNA Polymerase with Standard Taq Buffer
(M0273). https://www.neb.com/protocols/0001/01/01/taq-dna-polymerase-with-standardtaq-buffer-m0273
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The PCR mixture was placed in the PCR machine and set at a Standard 3-step PCR Cycling
with the following steps: initial Denaturation at 94°C for 1 minute (1 cycle), Denaturation
at 94°C for 1 minute (35 cycles), annealing at 61°C (35 cycles) (which was calculated using
the NEB Tm Calculator, extension at 72 °C for (35 cycles). The mixture was finally held
at 4°C. The thermocycling conditions for a PCR protocol is in table 4.
Table 4. The PCR thermocycling conditions
Step

Temperature

Time

Number of cycles

Initial denaturation

94°C

1 minute

1

Denaturation

94°C

1 minute

35

Annealing

61°C

1 minute

35

Extension

72°C

1 minute

35

Final extension

72°C

5 minutes

1

Hold

4°C

infinity

1

Adapted from PCR Protocol for Taq DNA Polymerase with Standard Taq Buffer
(M0273). https://www.neb.com/protocols/0001/01/01/taq-dna-polymerase-with-standardtaq-buffer-m0273
DNA agarose gel electrophoresis:
After PCR, a qualitative analysis was performed using the agarose gel electrophoresis.
10µL of PCR sample consisting of 10µL amplified mix and 2µL of (6X) gel Loading dye
was loaded on agarose gel and ran with 5µL of 1Kb DNA ladder to confirm amplification
of the target gene. The conduction of electrophoresis was at 65V for 40 minutes, and the
image was captured with a chemidoc camera.
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Purification of amplified target DNA
The amplified genes were purified using QIAquick PCR Purification Kit (50) (cat. nos.
28104), adopting the QIAGEN® PCR purification kit protocol (pages 22-23). 200µL (5
volumes) of Buffer PB was added to 40µL (1 volume) of the PCR reaction and mixed. The
mixed sample was added into a QIAquick column and placed in a 2mL collection tube
provided. The PCR sample was centrifuged at 13,000 rpm for 1 minute. The flow-through
was discarded. 750µL of Buffer PE was added to the QIAquick column and centrifuged
for 1 minute. The flow-through was discarded, and the tube was centrifuged for an
additional 1 minute. The QIAquick column was placed in a 1.5 ml microcentrifuge tube
and eluted with 30 µL Buffer EB. The PCR eluted was collected, and the concentration
was determined. The concentration of the eluted PCR mix was 25.7ng/µL, and the volume
eluted was 30 µL
3.1.2 Double restriction digestion of vector and purified target DNA
BamhI and XhoI restriction enzymes were used to digest the DNA fragment and vector,
pET28a. The New England Biolabs (NEB) protocol was used for the double restriction
digestion protocol [https://nebcloner.neb.com/#!/protocol/re/double/BamHI,XhoI]. The
digestion of both the target and plasmid were performed in 2 separate reactions. The
components were added in the other from top to bottom in Tables 6 A and B.
For the restriction digestion of the eluted PCR mix, 16µL Autoclaved water, 5µL of 10x
NEBuffer 3.1, 2µL (40 units) of XhoI, 2µL (40 units) of BamHI, and 25µL (642.5ng) of
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PCR mixture (Table 5A) mixed by gently flickering the tube, spun briefly, and incubated
for 1 hour at 37°C. The pET28a was digested by adding 40µL Autoclaved water, 5µL of
10x NEBuffer 3.1, 2µL (40 units) of XhoI, 2µL (40 units) of BamHI, and 10µL (500ng) of
pET28a (Table 5B) mixed by gently flickering the tube, spun briefly, and incubated for 1
hour at 37°

Table 5. Restriction digestion setup for A. eluted PCR mix and B. pET28a restriction.
B

A
Component

Volume (µL)

Component

Volume (µL)

Autoclaved water

40

Autoclaved water

40

10x Neb 3.1 buffer

5

10x Neb 3.1 buffer

5

BamhI

2 (40 units)

BamhI

2 (40 units)

XhoI

2 (40 units)

XhoI

2 (40 units)

MtMetAP1c DNA

25 (642.5 ng)

pET28a

10 (500 ng)

Adapted from “ Restriction Enzyme Double Digestion”, NEBcloner New England Biolab
Retrieved from https://nebcloner.neb.com/#!/protocol/re/double/BamHI,XhoI
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Agarose gel electrophoresis of digested genes:
Digested pET28a and MtMetAP1c were loaded on agarose gel. 10µL of (6X) Gel Loading
Dye, and 50µL of each digested DNA. 30µL of each is loaded into two lanes of the agarose
gel: Lane 3 and 4: digested pET28a (250ng per lane); Lane 5 and 6: digested MtMetAP1c
(321.25ng per lane) . Lane 2: Uncut pET28a (7µL autoclaved water, 2µL of 6x Gel Loading
Dye, and 150ng (3µL) of uncut pET28a), Figure 19. The gel ran for 90 minutes at 65 volts.
The next step was to extract the digested vector and target gene from the gel using the
Qiagen QIAquick gel extraction kit (cat # 28704) (pages 30 to 32) and adopt the kit's
protocol. After electrophoresis, the bands on the gel containing the digested pET28a (M3
&M4) and digested amplified target gene (M5 &M6) was excised from the agarose gel.
The excised bands were weighed; 409 mg of (M3 &M4) gel band and 473mg of (M5 &M6)
gel band. Three volumes of buffer QG (100mg approximately equals 100µL) that is 1227
µL buffer QG for excised (M3 &M4) and 1419 µL of buffer QG was added to excised (M5
&M6). Both excised gels were incubated at 50°C for 10 minutes to dissolve the gel. One
volume of isopropanol was pipetted to both excised gel samples, that is, 409µL of
isopropanol for (M3 &M4) dissolved mixture, and 473µL of isopropanol for (M5 &M6)
dissolved mixture. Mix and place a QIAquick spin column in a provided 2 ml collection
tube. The samples were added to the QIAquick column and then centrifuged at 13,000rpm
for 1 minute. The flow-through was discarded and repeated until all the samples were
filtered. 0.75 mL of Buffer PE was added into the QIAquick column, and the centrifuge
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allowed it to stand for 5 minutes, then centrifuged at 13,000rpm for 1 min. The flowthrough was discarded and further centrifuged for another 1 minute at 13,000rpm. The
QIAquick column was placed in a 1.5 ml microcentrifuge tube, and the DNA was eluted
with 50 µL of Buffer EB and centrifuged in the column for 1 minute. The concentrations
of the eluted DNAs were measured using a nanodrop: eluted MtMetAP1c gene:
10.85ng/µL, volume of eluted MtMetAP1c: 28µL and eluted pET28a: 9.4ng/µL, volume
of eluted MtMetAP1c: 28µL
3.1.3 Ligation of digested target DNA and vector
Ligation was carried out using two molar ratios of the target DNA to vector: 5:1 and 7:1
adopting

the

NEB'

Ligation

Protocol

with

T4

DNA

Ligase

(M0202)'.

https://www.neb.com/protocols/0001/01/01/dna-ligation-with-t4-dna-ligase-m0202. The
NEB calculator, 'https://nebiocalculator.neb.com/#!/ligation,' was used to calculate molar
ratios. Insert DNA length: 858bp, vector DNA length: 5369bp, vector DNA mass: 100 ng
111.9ng of eluted MtMetAP1c gene mass and 100ng eluted pET28a gene mass was used
for the 7:1 molar ratio ligation setup, while 39.95ng of eluted MtMetAP1c gene mass and
50ng eluted pET28a gene mass was used for the 5:1 Molar ratio.
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Table 6. Ligation set up for 7:1 DNA molar ratio.
Component

20 μL reaction

T4 DNA Ligase Buffer (10X)

2 μL

MtMetAP1c gene

10.64 μL (111.9 ng)

pET28a

10.63 μL (100 ng)

T4 DNA Ligase

1μL

Nuclease-free water

to 20 μL

Adapted from Ligation Protocol with T4 DNA Ligase (M0202) Retrieved from
https://www.neb.com/protocols/0001/01/01/dna-ligation-with-t4-dna-ligase-m0202
The outline for components added for the Ligation using a 20 µL reaction for both molar
ratios are stated in Tables 7 and 8. The components were gently mixed and centrifuged
briefly, and incubated overnight at 16°C
Table 7. Ligation set up for 5:1 DNA molar ratio
Component

20 μL reaction

T4 DNA Ligase Buffer (10X)

2 μL

MtMetAP1c gene

3.68 μL (39.95 ng)

pET28a

5.32 μL (50 ng)

T4 DNA Ligase

1μL

Nuclease-free water

to 20 μL

Adapted from Ligation Protocol with T4 DNA Ligase (M0202). Retrieved from
https://www.neb.com/protocols/0001/01/01/dna-ligation-with-t4-dna-ligase-m0202
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3.1.4 Transformation of E.coli cells, non-expression, and expression host, with the
recombinant DNA
The recombinant plasmid, pET28a-MtMetAP1c, was first used to transform the nonexpression host, Escherichia coli DH5 alpha competent cells, the gene clone was extracted
and purified from the non-expression host cell using the The QIAGEN Plasmid Plus Midi
Kit and adopting the kit protocol. Both molar ratios of ligated genes, recombinant DNA,
were used to transform a non-expression bacteria competent cell, and the Thermo Fisher
scientific Transforming Chemically Competent Cells protocol WAS adopted. The
competent cells, DH5α Competent Cells, were put into four aliquots of 50 µL and pipetted
into four vials left on the ice. For the ligation reaction vials, add 4µL of ligation mix (7:1
molar ratio) and 2µL of ligation mix (5:1 molar ratio). Incubate on ice for 30 minutes. The
mix is incubated for 30 seconds in the 42°C water bath then placed on ice after heat shock.
250 µl of pre-warmed Listeria broth (LB) medium was added to each vial and is shaken at
225 rpm for exactly 1 hour at 37°C. 200 µL is plated on an LB agar plate with 50μg/mL
Kanamycin (Catalog number: J60540.EQF); the LB agar plate is inverted and incubated at
37°C overnight. For the control setup, 1µL of pET28a for vector control and 2.5µL of
pUC19 control in place of the ligated mix. The same procedure is carried out for the control
setup. The puC19 control mix is spread on an LB Agar plate with 100μg/mL Ampicillin
(Catalog number: J63197.EQF)
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Figure 14. Transformation of non-expression DH5α Competent Cells with the
recombinant plasmid. Kan: Kanamycin, amp: ampicillin.

3.1.5 Culturing of transformed non-expression competent cells
The colonies of transformed DH5 alpha competent cells with recombinant genes
(MtMetAP1c-pET28a grown on the plates were collected and cultured in LB medium. Two
colonies from the 7:1 molar ratio plate and one colony from the 5:1 molar ratio plate. One
colony is added to 25mL of sterile LB culture containing 30ug/mL of Kanamycin by adding
15μL of 50 mg/mL kanamycin into 24mL 985μL of LB. The inoculated medium was
incubated overnight at 37°C, shaking at 225 rpm. The following morning the culture is

68
divided into 2, that is, four aliquots of 12mL for the 7:1 molar ratio culture and two aliquots
of 12mL for the 5:1 molar ratio culture. The protocol was adapted from ‘QIAwave Plasmid
Miniprep Handbook. For purification of molecular biology–grade DNA’, page 21-24
https://www.qiagen.com/us/products/discovery-and-translational-research/dna-rnapurification/dna-purification/plasmid-dna/qiawave-plasmid-kits/. The overnight culture
was centrifuged at 5000 rpm for 10 minutes at 20°C. The bacterial cell pellets obtained
were resuspended in 600 μL buffer P1 mixture (10 μL of lyse blue added to 10mL buffer
P1: for a final dilution of 1:1000) and agitated until the pellet was mixed. 250 μL of Buffer
P2 was added to the cell suspension and mixed by inverting about 6 times. 350 μL of buffer
N3 was added to the mixture and mixed by inverting the tube until a colorless suspension
was obtained. The suspension was spun for 10 minutes at 13,000rpm, and the filtrate,
800μL, was collected, loaded to the Spin Column, and centrifuged for 1 minute at
13,000rpm. The flow-through was discarded, and 750 μL of Buffer PB was added to the
QIAprep 2.0 Spin Column and washed for 1 minute at 13,000rpm. The QIAprep 2.0 Spin
Column was added to a 1.5mL Eppendorf tube, and 100 μL Buffer EB was added to the
column and allowed to stand for 1 minute before spinning for another 1 minute at
13,000rpm. The eluted plasmid was collected as the flow-through from the column. The
concentration of the eluted plasmid derived from the transformed DH5 competent cells was
55.6ng/mL and 108.5ng/mL for both colonies 1 and 2 from the 7:1 molar ratio recombinant
plasmid. The concentration from eluted plasmid for colony three from 5:1 molar ratio
recombinant plasmid was 100.5ng/mL. 20μL aliquots of the eluted DNA (plasmid) was
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sequenced by the University of Texas MD Anderson Genetics department core facility,
advanced technology genomics core department of genetics. The sequence result obtained
showed that the 5:1 molar ratio recombinant DNA was free of the mutation. This was
confirmed by using the NCBI blast software to perform sequence alignment analysis. The
mutation-free plasmid was further used to transform an e. coli expression host.
3.1.6 Transformation of E.coli BL21 (DE3) competent cells with the recombinant
DNA
The E. coli expression host, Escherichia coli BL21 DE3, was transformed with the clones
of mutant free recombinant plasmid for the overexpression of the MtMetAP1c protein. The
purchased kit protocol was adopted for the transformation protocol. Manual: OneShot
BL21(DE3), One Shot BL21(DE3) pLysS and One Shot BL21(DE3) pLysE. ‘Basic
Transformation Procedure’ (pages 5- 6)
(https://www.thermofisher.com/order/catalog/product/C600003?SID=srch-srp-C600003)
The eluted plasmid (without mutation) from the 5:1 molar ratio gene was first diluted from
106.5ng/µL to make a final concentration of 1ng/µL and 4ng/µL. 0.275µL of the stock
eluted plasmid was added to 29.724µL Buffer EB to produce 1ng/µL concentration, while
0.737µL of stock eluted plasmid was diluted with 19.262µL of buffer EB to produce 4ng/L
final concentration. 5µL of 1ng/µLand 2.5µL of 4ng/µL was used to transform 50µL E.
coli BL21 (DE3) competent cells, respectively. For the control, 1uL (10 pg) of puC19 and
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1µL (10 ng) pET28a were added to 50µL of the competent cells. The mixture of gene and
E.coli cells was gently mixed and incubated on ice for 30 minutes. The mixture was heatshocked at 42 °C in a water bath for 30 seconds, then quickly incubated on ice 250 μL of
pre-warmed LB medium was added to the vial of the mixture and shook at 225rpm for 1
hour at 37°C. 200µL of the bacteria culture transformed with 5ng DNA and 100µL of the
bacteria culture transformed with 10 ng DNA is plated on an LB Agar plate with 50μg/mL
Kanamycin, respectively. 50µL (500pg) of pUC19 and 100µL (100 ng) of pET28a was
spread on an LB agar plate containing 100 µL/mL ampicillin and 50µLug/mL Kanamycin,
respectively. The LB agar plates were inverted and incubated overnight at 37°C. A single
colony was picked the following morning and stored in 25% glycerol, and kept in -80°C.

3.2 Overexpression and purification of MtMetAP1c
3.2.1 Small scale MtMetAP1c overexpression
A mini-pilot overexpression of the protein to determine the optimum post-induction harvest
of cells time was conducted. 4mL 995µL of LB media was pipetted into tubes 1, 2,3,4,5,
6, 7, and 8.
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Table 8. Small scale MtMetAP1c overexpression post induction time set up

Tube

Harvest time Post induction (hour)

1

1mL E. coli culture at 0 hour prior to induction

2

1mL uninduced E. coli culture 2 hours after induction

3

1mL induced E. coli culture 2 hours post induction

4

1mL uninduced E. coli culture 4 hours after induction

5

1mL induced E. coli culture 4 hours post induction

6

uninduced E. coli culture 8 hours post induction

7

1mL induced E. coli culture 8 hours after induction

Scope BL21 DE3 glycerol stock into a 12mL tube containing 5mL and 30 µg\mL
kanamycin. This culture was incubated at 37◦C and shaken in a Brunswick shaker at
275rpm overnight. The following morning 100µL (1:50) of the overnight culture was
inoculated into tubes 1, 2, 3, 4, 5, 6, 7, and 8 LB containing 30 µg\mL kanamycin and
further incubated at 37◦C, shaking at 275rpm. 1mL of a sample is taken from tube 1
Immediately prior to induction of cells. The growth of the E.coli cells was monitored until
an optical density (O.D600 ) of 0.6-0.8 was reached. At an O.D600 of 0.61. At this O.D600 of
0.61, 5µL of 1M Isopropyl ß-D-1-thiogalactopyranoside (IPTG), at 1 mM IPTG final
concentration, was added to tubes 3, 5, and 7 and incubated at 16◦C shaking at 280rpm.
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1mL of samples was taken from tubes 2 and 3 2 hours after induction. After 4 hours of
induction, 1mL samples were taken from tubes 4 and 5. 1 mL sample was taken from tubes
6 and 7 8 hours after induction. The samples were spun at 3500 rpm, the supernatant was
discarded, and the pellets were dissolved with 50 µL buffer (50mM HEPES, 100mM NaCl,
pH 7.5), vortexed, and centrifuged at 8,100rpm for 2 minutes. 20 µL of 2x Lammelli buffer
was added to 20 µL of the cells and heated for 5 minutes at 95◦C. 10 µL of the samples
were loaded on a gel, and the sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) was conducted to qualitatively determine the optimum post expression
harvest time.
3.2.2 Scale-up of MtMetAP1c overexpression
A single colony of BL21-DE3 cells obtained from small scale culture plate was grown
overnight at 37◦C, 275rpm, in 100mL LB containing 30 µg\mL kanamycin. The next
morning, the overnight culture was cultured in 4 Liters of LB media containing 30 µg\mL
kanamycin at 37◦C at the same speed of rotation. 1 mL sample of the uninduced culture
was taken for SDS analysis. The incubated culture was monitored until an O.D600 of 0.60.8 was reached. The target protein is subsequently induced by the addition of 1mM IPTG
final concentration (4mL of 1M IPTG) at an O.D600 of 0.678 and further cultured at 16 ◦C
for 8 hours at 280 rpm before the harvest of cells. The 8 hours post-induction was selected
for the harvest of cells based on previous preliminary mini-pilot overexpression. 1mL of
the induced cells was taken for gel analysis, and the induced cells were harvested in 1X
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Phosphate-Buffered Saline (PBS). The pellets were incubated in 30mL ice-cold lysis buffer
(0.4% Triton X-100, 1xPBS, 10% glycerol, and EDTA-free protease inhibitor tablets, and
20mM Imidazole) and incubated on ice for 1 hour prior to sonication of the cells. The cells
were sonicated in a lysis buffer using the Branson SFX250 Sonifier. The cells were
sonicated, with 35 cycles for 15 sec with 30 seconds pause on ice between each burst.

Figure 15. Overview outline for overexpression and purification of MtMetAP1c
The lysate was Centrifuged at 5000g for 1 hour at 4°C to pellet any insoluble material. The
supernatant was gently collected without disturbing the pellet. 1mL of both supernatant
and pellet was reserved at 4°C for SDS/PAGE analysis. The protocol for the purification
was adopted with slight modifications from TALON® Metal Affinity Resins User Manual,
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pages 29-31 (http://www.takara.co.kr/file/manual/pdf/pt1320-1.pdf). The harvested cells
were in 1X PBS and sonicated in a lysis buffer (0.4% Triton X-100, 1xPBS, 10% glycerol,
and EDTA-free protease inhibitor tablets, and 20mM Imidazole. The cell lysate was
centrifuged at 5000g for 1 hour and the clarified protein was retrieved for the purification
process. The supernatant was further purified through the Immobilized metal affinity
chromatography (IMAC) technique. The MtMetAP1c clarified protein was incubated for
1 hour to pre-equilibrate His Pur™ Nickel Nitrilotriacetic Acid (Ni-NTA) Resin, a sample
of beads after protein binding was taken for SDSPAGE analysis. The beads were washed first and the second time with wash buffer (50
mM HEPES [pH 8.0], 100mM NaCl, 10% glycerol, and 20mM Imidazole), then finally
washed the third time with wash buffer (50 mM HEPES [pH 8.0], 100mM NaCl, 10%
glycerol, and 40mM Imidazole) and eluted with elution buffer containing 75mM Imidazole
Figure 19. The elution was repeated twice. 1mL of each elution and beads after final elution
was taken for SDS-GEL analysis. The average yield of MtMetAP1c was determined with
the Thermo Scientific NanoDrop UV-Vis spectrophotometer, which was 4.65mg per liter
of E.coli culture. The efficiency of the expression and purification protocol of the protein
was determined by running an SDS-PAGE of the cell lysate and the supernatant. The
average

yield,

quantified

with

the

Thermo

Scientific

NanoDrop

spectrophotometer, was 4.65mg of mtMetAP1c per liter of E.coli culture.

UV-Vis
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3.3 Preliminary evaluation of MtMetAP1c divalent metal dependence
Firstly, the activity of eluted MtMetAP1c was determined. An enzymatic assay screen to
determine the NME ability of the cobalt ion activated MtMetAP1c and the concentration
of the protease required for optimum activity was performed. The enzymatic assay was a
slight modification of the method adopted by Zhou et al and Olaleye et al [Zhou et al.,
2000; Olaleye et al., 2010], by using a monopeptide substrate and the assay incubated for
1 hour. The reaction was performed at 37◦C in a 96-well plate and activity monitored on a
spectrophotometer at 405 nm. Each well had a total of 100 µL reaction containing 50mM
HEPES buffer (pH 8), 100mM NaCl, 15 µM CoCl2, 100 µg/mL BSA, 1mM chromogenic
substrate (L-Methionine para nitroanilide) purchased from sigma Aldrich, CAS Number:
6042-04-2. The MtMetAP1c cleaves the L-Methionine para nitroanilide to form
methionine and the chromogenic p-Nitroaniline. p-Nitroaniline absorbs the white light
spectrum at 405 nm. The 100 µL reaction was incubated for 1 hour at 37°C in a 96-well
plate, and activity was monitored on a spectrophotometer [Molecuar Devices SpectraMax
iD3 Multi-Mode Microplate Reader] at 405 nm. Each well contains 50mM HEPES,
100mM NaCl buffer (pH 8), 15 µM CoCl2, 100 µg/mL BSA, 1mM chromogenic substrate
(L-Methionine para nitroanilide), and purified MtMetAP1c. The concentration range for
the enzyme in each plate: 4.19, 8.38, 10.48, 12.58, 16.77, and 20.96 µM (Table 8). A unit
of enzyme activity is defined as 1 µM of the substrate product, nitroanilide per minute
under the stipulated experimental condition.
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Table 9. The concentrations of MtMetAP1c in each assay well for the MtMetAP1c
divalent metal dependence
Molecular
weight
(kDa)

Concentration
of
MtMetAP1c
(µg/uL)

Volume of
MtMetAP1c
(µL)

Mass of
MtMetAP1c
(µg)

Concentration
of
MtMetAP1c
per well
(µg/uL)
0.13

Concentration
of MtMetAP1c
per well (µM)

13.42

Assay
volume
per
well
(uL)
100

32

2.68

5

32

2.68

10

26.83

100

0.27

8.38

32

2.68

12.25

33.54

100

0.34

10.48
12.58

32

2.68

15

40.25

100

0.40

32

2.68

20

53.66

100

0.54

16.77

32

2.68

25

67.08

100

0.67

20.96

4.19

The absorbance was measured with the spectrophotometer at 405 nm after 1-hour
incubation. An enzyme activity calibration curve consisting of the concentration of the
enzyme at the x-axis and the corresponding concentration absorbance on the Y-axis was
plotted to determine (i) if the enzyme is active (II) the optimum concentration of the
enzyme that produces an N-terminal methionine excision from the substrate to produce the
chromogenic functional group, p- nitroanilide.
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Figure 16. Diagrammatic representation of the in vitro enzymatic assay.
Adapted from “Two continuous spectrophotometric assays for methionine
aminopeptidase”, by Zhou, Y., Guo, X. C., Yi, T., Yoshimoto, T., & Pei, D. (2000).
Analytical Biochemistry, 280(1), 159–165. https://doi.org/10.1006/abio.2000.4513

A preliminary MtMetAP1c metal dependence activity was conducted. The cobalt (II) and
nickel (II) ions were determined by assaying the catalytic effect of MtMetAP1c by adapting
the same colorimetric assay stated above [Zhou et al., 2000; Olaleye et al., 2010]. The
extinction coefficient of p-nitroaniline was 9.96 mM–1 cm–1 and was used for the
calculation of enzyme activity. The activity of MtMetAP1c is expressed as the amount in
µM of p-Nitroanilide released per minute per mL protein.
Cobalt (II) chloride anhydrous (catalog number: 7791-13-1) purchased from sigma Aldrich
and a stock of 10mM in aqueous solution. A metal was serially diluted in water, and the
final concentration of 0.1, 1, 10, 100, 1000, 10,000 µM and volume 10 µL per well. The
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specific divalent metal concentrations that catalyzed the highest activity of MtMetAP1c
were selected for subsequent in vitro compound inhibitory effect

Table 10. Activation of MtMetAP1c using different concentrations of (A) cobalt (II)
chloride and (B) nickel (II) chloride

A
Concentration Absorbance
OD600
of CoCl2 (µM)

No metal

0.16

0.1

0.14

1

0.12

10

0.14

100

0.61

1,000

0.35

10,000

0.12

B
Enzyme
activity (µM
mL-1 min-1)

72.03
62.80
51.32
62.66
267.81
152.85
53.89

Concentration
of NiCl2 (µM)

Absorbance
OD600

Enzyme
activity
(µM mL-1
min-1)

No metal

0.16

87.02

0.1

0.12

52.03

1

0.13

63.62

10

0.08

35.50

100

0.59

258.82

1,000

0.25

108.06

10,000

0.24

105.70

screens. The test wells contain 33.4 µg (10.48 µM) MtMetAP1c, buffer (50mM HEPES,
100mM NaCl, 100 µg/ mL BSA pH 7.5). The microplate was incubated at 37◦C for 1 hour,
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the absorbance was measured at 405 nm using a spectrophotometer, and the corresponding
enzyme activity was calculated [Table 10 A and 10 B].
Extinction coefficient of p-nitroaniline 9.96 mM-1 cm1, pathlength in a 96 well microplate
assay can be assumed to be around 2–5 mm (0.5cm)
A plot of the in vitro activity of MtMetAP1c against the corresponding NiCl2 was
performed. The metal control had no NiCl2, the blank had no enzyme, and the controls
were subtracted from the corresponding assay reaction. All experiments were performed
in duplicates. An identical preliminary enzyme dependence screen was conducted using
Nickel (II) chloride hexahydrate (catalog number: CAS Number: 7791-20-0) as a cofactor.
The concentration of the metals that activated MtMetAP1c the most was used to perform
the compound inhibitory effect screen.

3.4 Evaluation of in vitro inhibitory effect of OJT008 against divalent nickel and cobalt
activated

MtMetAP1c

The half-maximal inhibitory concentration (IC50) of OJT008 for MtMetAP1c was
evaluated. Based on the optimum activity obtained from the enzyme using Nickel chloride
and cobalt (II) chloride, MtMetAP1c is activated with 100 µM CoCl2 and 100 µM NiCl2.
50mM stock of the test compound in DMSO was prepared and serially diluted in DMSO
to obtain a final concentration of 500 µM to 1 µM in each assay well in a 96 well plate.
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The reaction was carried out in triplicates. Each reaction well contains a buffer (100 mM
NaCl, 50 mM HEPES buffer (pH 8), 100 µg/mL BSA, and 100 µM of CoCl2. The reaction
was incubated for 20 minutes at 37°C, then subsequently incubated with the substrate for
an hour at the same temperature. The reaction was monitored at a wavelength of 405 nm.
Drug-free and DMSO media were used as controls. The background hydrolysis was
corrected, and the data were analyzed with four-parameter (variable slope) equations using
GraphPad Prism software. The identical assay was repeated using 100 µM of NiCl2. The
reaction was carried out in triplicates.
3.5 In silico evaluation of the mechanism of action of OJT008 against MtMetAP1c
Molecular Docking

and Simulation

MtMetAP1c Acquisition and Preparation
X-ray crystal structures of Nickel and Cobalt ions bound MtMetAP1c, PDB code: 3IU8
and PDB code: 1YJ3 were obtained from the RSCB Protein Data Bank [Lu et al., 2010b;
Addlagatta et al., 2005]. The structures were then prepared on the UCSF Chimera software
package [Yang et al., 2012]; the proteins were prepared by removing water molecules,
nonstandard naming, and protein residue connectivity. The 3-D structure of OJT008 was
prepared on the Avogadro software package [Hanwell et al., 2012].
Molecular Docking
Autodock vina available on Chimera version 1.14 was used for molecular docking analysis
(Trott and Olson, 2010), with default docking parameters. Before docking, Gasteiger
charges were added to the molecules, and the non-polar hydrogen atoms were merged to
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carbon atoms. The molecules were then docked into the proteins' binding pocket, by
defining the grid box with a spacing of 1 Å each and size and (18× 31 × 21) and (21 × 27
× 17) pointing in x, y and z directions, respectively. The protonation state of the target was
performed before docking calculations. Exhaustiveness number eight was used. The
molecular docking scores of OJT008 for both Nickel and Cobalt ions were estimated.
3.6 Determination of the potency of OJT008 against drug-sensitive Mtb and
Multidrug resistant-Mtb
OJT008 (purchased from Molport) potency against both Mtb cells, drug-sensitive Mtb type;
strain CDC 1551 and MDR-TB type; Mtb HN 3409 strain, were determined using serial
dilution broth. The compound screen was conducted in collaboration with Houston
Methodist Research Institute. A 5mL 7H9 medium was modified to produce a working
culture medium by pipetting the 4807.5 µL 7H9 medium to 90 µL of 2 % glycerol, 2.5 µL
of 0.05% Tween-80. The medium was further modified by adding 10% albumin /dextrose
complex. The Mtb cells were first grown to an Optical density (O.D) of 1.0. Mtb CDC
1551 and Mtb HN 3409 were grown to an OD of 1.07 and 1.01, respectively. The culture
was further diluted to 1:10 dilutions by adding the 100µL of the Mtb culture (O.D of 1)
with 900µL of 7H9 medium. The bacteria cells were further diluted to 1:100 dilution with
the 7H9 medium by adding 300µL of Mtb culture (OD of 1:10) into 2700µL 7H9 medium
to produce a 1:100 dilution. OJT008 was serially diluted in DMSO to produce 5, 1, 0.5,
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0.25, 0.1, 0.05, 0.025, 0.0125, and 0.00625 mg/ mL. 50 µL of serially diluted OJT008 was
added to the culture medium was added to the culture medium described above to produce

Dilution of Mtb: OD 1
≥ 1/10 ≥ 1/100

Figure 17. Determination of minimum inhibitory concentration of OJT008 in Multi
drug resistant Mtb
a corresponding concentration of 50, 10, 5, 2.5, 1, 0.5, 0.25, 0.125, and 0.0625 µg/mL final
concentration and incubated at 37°C. Kanamycin and Isoniazid were used as the positive
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control for the MDR-TB and drug-sensitive Mtb and, respectively. OJT001 was used as a
reference control compound. The blank control had 50 µL DMSO without a test compound.
The reaction was carried out in duplicates, and CDC 1551 strain was incubated for two
weeks while HN 3409 was incubated for four weeks. The incubated culture was visually
observed to determine the presence or absence of Mtb growth

Table 11. Outline for the setup for compound antibacterial screen
Compound
screen
(µL)

Reference
control (µL)

Positive
control
(µL)

Negative
control
(µL)

CDC
1551
strain

HN
3409
strain

CDC
1551
strain

HN
3409
strain

CDC
1551
strain

HN
3409
strain

CDC
1551
strain

HN
3409
strain

OJT008

50

50

__

_

__

__

__

__

OJT001

__

__

50

50

50

50

__

__

Kanamycin

__

__

__

__

__

50

__

__

Isoniazid

__

__

__

__

50

__

__

__

7H9 broth

4850

4850

4850

4850

4850

4850

4850

4850

DMSO

__

__

__

__

__

__

50

50

Mtb culture

100

100

100

100

100

100

100

100
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CHAPTER 4
RESULTS AND DISCUSSION
4.1 Amplification of MtMetAP1c gene from Mtb H37Rv genome
The study accomplished the aim of cloning, overexpressing, and purifying the expressed
recombinant target protein, MtMetAP1c, with the N-terminal end of the sequence tagged
with the 6x poly-histidine. To successfully characterize OJT008 as an inhibitor of Mtb,
MtMetAP1c was generated through cloning, and the protease was overexpressed, purified
to its homogenous state, and in vitro activity determined. The amplified gene produced a
prominent band corresponding to the 858bp for MtMetAP1c, corresponding to the 1 kb
DNA marker on agarose gel (Figure 18).

Figure 18. Agarose gel scan showing PCR product
Lane 1 (M1): 5µL of 1Kb DNA ladder, Lane 2 (M2): amplified MtMetAP1c gene.
The overexpression of MtMetAP1c was achieved by constructing a recombinant pET28aMtMetAP1c using digestion enzymes (Figure 19)
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Figure 19. Agarose gel scan showing controls and digested DNA.
Lane 1 (M1):5µL of 1Kb DNA ladder, Lane 2 (M2): undigested vector; pET28a (150 ng),
Lane 3 & 4 (M3 &M4): digested vector (250 ng each), Lane 5 & 6 (M5 & M6): digested
amplified target gene (321.25ng) each.

The recombinant DNA was successfully used to transform Escherichia coli DH5 alpha
competent cells. A colony from the purified recombinant plasmid, 5:1 insert gene to vector
molar ratio, was obtained with no mutation.
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Figure 20. DNA sequence alignment using the NCBI blast software using forward and
reverse primers (Left to right): sequencing of the gene at the University of Texas MD
Anderson genetics department core facility.
and successfully transformed into E. coli BL21 (DE3) competent cells (Figure 21 a and b).
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Figure 21. Transformed expression E. coli BL21 (DE3) with the recombinant plasmid
5ng and 10ng A. Competent cells transformed with 5ng Recombinant plasmid B.
Competent cells transformed with 10ng Recombinant plasmid.
The mini pilot overexpression of transformed expression host cells showed an optimized
expression 8 hours post induction for cells transformed with pET28a-MtMetAP1c (Figure
22).
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Figure 22. Mini induction pilot of Recombinant MtMetAP1c from Mtb gene at
different time intervals. Lane 1, Molecular weight marker; lane 2, uninduced whole cell
lysate; lane 3, uninduced cell lysate at 2 hours post-induction, lane four induced cells at 2
hours post-induction; lane 5 uninduced cells at 4 hours post-induction lane 6 induced cells
at 4 hours post-induction lane 7 uninduced cells at 8 hours post-induction lane eight
induced cells at 8 hours post-induction.
4.2 Overexpression and purification of MtMetAP1c
An 8 hour post-induction harvest time of overexpressed MtMetAP1c in E.coli BL21
competent cells was required for optimum yield of the enzyme, as confirmed by performing
a qualitative SDS-PAGE analysis. A total of 4.65mg of MtMetAP1c was eluted from a liter
of E.coli culture, and an in vitro enzymatic assay showed that the purified MtMetAP1c is
its highest activity at 10.48 µM as shown by the nitroanilide production from the
chromogenic substrate with the absorbance monitored using a spectrophotometer at 405
nM. The overexpressed protein was purified by IMAC using His Pur™ Ni-NTA Resin.
The purified and N-terminally poly-His-tagged MtMetAP1c appeared as a band
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corresponding to the 32 kDa on Coomassie blue-stained SDS-polyacrylamide gel (Figure
23). The average yield of MtMetAP1c from 1 liter of the BL21 (DE3) culture was 4.65mg.

Figure 23. SDS–PAGE analysis of purified His-tagged MtMetAP1c protein using Ni–
NTA-affinity chromatography. A. Lane 1, protein weight marker; lane 2, uninduced
whole cell lysate; lane 3, induced cell lysate taken after 8 hrs; lane 4, Pellet after sonication;
lane 5, Supernatant containing clarified protein after sonication; lane 6, Beads after final
binding; lane 7, Beads after final elution; lane 8, Elution 1 (using 75mM Imidazole); lane
9, Elution 2 (using 75mM Imidazole) lane 10, Elution 3 (using 75mM Imidazole).
An 8 hour post-induction harvest time of overexpressed MtMetAP1c in E.coli BL21
competent cells was required for optimum yield of the enzyme, as confirmed by performing
a qualitative SDS-PAGE analysis. A total of 4.65mg of MtMetAP1c was eluted from a liter
of E.coli culture, and an in vitro enzymatic assay showed that the purified MtMetAP1c is
its highest activity at 10.48 µM as shown by the nitroanilide production from the
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chromogenic substrate with the absorbance monitored using a spectrophotometer at 405
nM. Based on enzymology studies, different factors contribute to the activity of a protease
[Grahame et al., 2015]. In a previous study by Olaleye et al. the concentration of the
enzyme required for the optimum activity of MtMetAP1c is 334 nM. In this study, 10.48
µM of MtMetAP1c was required for the optimum in vitro NME activity, approximately 31
times higher than the previous studies [Olaleye et al., 2010]. Although the plasmid and Mtb
genome strain used was different from the study by Olaleye et al. and considering all other
physical parameters required for the protease activity were maintained in the laboratory, a
study by Zhang et al. suggested that the length of substrate peptide used for the
chromogenic assay determines the level of activity of MtMetAP1c [Zhang et al., 2009].
They discovered that MtMetAP1s were more active with tetrapeptide substrate compared
to the tripeptide counterpart. Dipeptide substrate, dipeptide, methionine-proline coupled to
p-Nitroaniline, was used in Olaleye et al. study [Olaleye et al., 2010], while in this study,
a monopeptide chromogenic substrate, L-Methionine ρ -nitroanilide was used for the in
vitro assay. However, Naanan et al. assay suggested both MtMetAP1a and MtMetAP1c
exhibited the highest specific activity when L-Methionine ρ -nitroanilide was used as the
substrate [Narayanan et al., 2012]. The specific substrates used with other adopted assay
parameters may explain the observed enzyme activity difference.
4.3 Preliminary evaluation of MtMetAP1c divalent metal: Nickel, dependence
In this study, the purified MtMetAP1c generated was discovered to be activated by both
Nickel and cobalt (II) ions. The preliminary enzyme metal-dependent screen showed both
divalent metal salts, NiCl2 and CoCl2, optimum activation of MtMetAP1c is at the same
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concentration of 100 µM and produced approximately the same activity 258.8 µM mL-1
min-1 and 267.8 µM mL-1 min-1(Figure 23 a and b).

Figure 24. Activity of MtMetAP1c in the presence of different concentrations of a)
Cobalt (II) chloride and b) Nickel (II) Chloride
The efficiency of Nickel ions in catalyzing MtMetAP1c is discovered to be significantly
lower than that of the Cobalt ions. In addition, this study showed that an increase in the
concentrations of the two metals higher than 100 µM inhibits the activity of MtMetAP1c,
as evidenced by the decrease in the enzyme's activity.
MetAPs are dinuclear metalloproteases and utilize divalent cofactors for their NME
functions. N-terminal methionine processing occurs in about 55-70% of nascent proteins
[Giglione et al., 2000]. A study by aerie et al. discovered that the activity of MetAP was
inhibited by EDTA, a metal chelating compound, which confirms the metalloprotease
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nature of the enzyme [Ben-Bassat et al.,1987]. Purified apo-form MetAP have been proven
to be consistently activated by divalent metal ions like Fe2+, Ni2+, Mn2+, and Co2+ [Arfin et
al., 1995; D'souza et al., 1999; Jing-Ya Li et al.,2003]. E. coli MetAPs are activated by
metal ions such as Ni2+, Fe2+, Co2+, Mn2+, and Zn2+ [D'souza et al., 2002]. Comparable
sizes of the divalent metal’s ions have made isomorphous replacement achievable. In
another study, Chai et al. showed that cellular e. coli Methionine aminopeptidase utilizes
Fe (II) for its activation [Chai et al., 2008]. Nonetheless, the specific biological metal (s)
required for MetAP catalytic activity is still debatable in contrast to PDF with an
established specific physiological metal [Rajagopalan et al.,1997; Rajagopalan et al.,2000].
In previous studies, the cobalt ion was believed to be the best cofactor for MetAP; this
postulation was backed by evidence of 2 cobalt (II) ions docked in the active site of the Xray structure of MetAP [Lowther., & Matthews, 2000]. Subsequently, the majority of
discovered MetAP inhibitors were characterized using MetAP activated with Co2+.
Paradoxically, a preponderance of pharmacophores selected with the specified cobalt
metallated MetAP was highly effective in inhibiting MetAP in vitro assays but lacked
significant potency against the corresponding bacteria [Luo et al., 2003; Douangamath et
al., 2004; Schiffmann et al., 2005].
MtMetAP1s, which are MetAP1 isoforms in Mtb, are known to be activated by certain
divalent metal ions [Zhang et al., 2009; Olaleye et al.,2010; Lu et al., 2010; Narayanan et
al.,2012]. Cobalt and nickel ions, however, have consistently been proven by different
groups through reproducible results to activate MtMetAP1 isoforms in their purified apoenzyme form [Olaleye et al.,2010, Jing-Ping et al., 2010; Narayanan et al., 2012]. The
MtMetAP1s and MetAPs from different bacteria cells, metal-dependent screens performed
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by different groups, discovered a similar trend of a bell-shaped divalent metal activation
curve which is in line with our Preliminary evaluation of MtMetAP1c divalent metal. It is
suggested that a progressive increase in the concentration of MtMeAP1c cofactors in the
active site causes an inhibitory effect.
The question of whether MtMetAP1a or MtMetAP1c was stripped off every possible such
imidazole or metal impurities from the host cell or beads used to purify the protease through
dialysis prior to the metal screen determines the true representation of the MtMetAP1metal screen performed. Hence the apo-form or holo-form of MtMetAP1 is critical for the
evaluation of MtMetAP1 divalent metal dependence. In contrast, Zhang et al. reported that
Co (II) activated both holoenzyme MtMetAP1a and MtMetAP1c, while nickel (II) and iron
(II) significantly inhibited the activity of the enzyme [Zhang et al., 2009]. However, JingPing et al used the purified apo-form of both MtMetAP1s to determine metal dependence
for activation and subsequently reported nickel ion to be an effective activator of both
MtMetAP1a and MtMetAP1c [Lu & Ye et al., 2010a], which is consistent with other
reports in which the apoenzyme form instead of the metallated form, was used. In this
study, the two metal ions, Ni2+ and Co2+, the optimum concentration required to activate
the holo-MtMetAP1c was determined. This screen is a preliminary evaluation of metal
dependence as the purified enzyme was not dialyzed to obtain its apo-form prior to
performing the metal screen. The obtained concentration of the metal will further determine
the evaluation of the OJT008 inhibitory effect against MtMetAP1c using the metal
concentration obtained from the screen. However, In a previous study, Narayanan et al
reported Ni2+ and Co2+ as activators of both MtMetAP1a and MtMetAP1c [Narayanan et
al.,2012]. They also discovered the maximum in vitro activity of apo-form MtMetAP1c
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occurred in the presence of 100µM of Ni2+ and Co2+, and excess metal ion binding resulted
in an approximate reduction of the catalytic effect by half [Narayanan et al., 2012]. This
report suggests our results may be less affected, at least, by metal impurities present in the
enzyme prior to the preliminary enzyme metal dependence screen. This suggests our holo
form MtMetAP1c activity was not affected by the presence of nickel beads used for the
enzyme purification. Our results showed a steady decrease in the activity of MtMetAP1c
from a concentration of 1000µM. This trend was also discovered by D'souza et al [D'souza
et al., 2000]
4.4 Evaluation of in vitro inhibitory effect of OJT008 against divalent nickel and
cobalt activated MtMetAP1c
The in vitro inhibitory effect of OJT008 against the NiCl2 and CoCl2 (at 100µM) activated
MtMetAP1c was evaluated (Figure 24). OJT008 inhibited the purified MtMetAP1c with
an IC50 value in a low micromolar concentration. The measured IC50 values of OJT008
against CoCl2 and NiCl2 (100µM) metallated MtMetAP1c are 11.81 µM and 40.12 µM,
respectively , Table 11.
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Figure 25. The inhibitory effect of OJT008 against the activity of metal activated
MtMetAP1c using a) 100 µM cobalt (II) chloride and b) 100 µM nickel (II) chloride

Table 12. The half-maximal inhibitory concentration of OJT008 Metal-activated
MtMetAP1c against 100uM Nickel (ii) chloride and 100µM Cobalt (II) chloride

Inhibitor ID

OJT008

Chemical structure

MtMetAP1c IC50 values
100µM CoCl2

100µM NiCl2

11.81 ± 1.30

40.12 ± 1.12
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In this study, we assayed the effect of OJT008 against nickel and cobalt ion activated
MtMetAP1c. The IC50 OJT008 against the cobalt ion activated MtMetAP1c was
approximately 3.5-fold lower than the nickel ion activated MtMetAP1c. The result suggests
the pharmacophore comparably binds to cobalt ion in the metalloprotease compared to
nickel ion. These findings suggest OJT008 is an effective MtMetAP1c inhibitor.
The challenge posed in the selection and design of MetAP inhibitors is the inadequate
information regarding the native metals in the active sites of the metalloprotease. Several
reasons exist for the disparity between in vitro and in vivo potency of a compound which
ranges from poor absorption of the compound into the pathogen cells or metabolic
processes of the bacteria. Another logical reason for these discrepancies in the potency of
MetAP inhibitors is the difference in the specific metals in the purified enzyme and the
metals utilized by the microorganism in the native form. Therefore, MetAP inhibitors can
be therapeutically useful if the potency is optimized by inhibiting the specific metal in
MetAPs in microbes. The reported mechanism of action of a preponderance of clinically
approved drugs that target metalloprotease is through the interaction with metal ions in the
catalytic site of the enzyme [Mullard et al., 2014; Chen et al., 2019].
Since inhibitors of metalloprotease usually interact with the metal ions sequestered in the
active site, MetAP inhibitors have varying potencies against different metallated proteases,
as previously proven in E. coli MetAP [Ye et al., 2004]. Fe2+ was previously determined
to be the native metal ion required for the activity of E. coli MetAP in E. coli. Furthermore,
E.coli inhibitors selective of the cell's Fe2+ metalloform form exhibited a potent
antibacterial effect [Chai et al., 2008]. A study by Lu et al. reported MtMetAP1c utilizes
Fe (II) in the E. coli cellular environment [ Lu et al., 2011]. To date, the specific metal ion
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utilized by MtMetAP1a and MtMetAP1c in Mtb is unknown. Lu et al. discovered
benzamide derivatives 4- 10 effectively inhibited MtMetAP1c by binding to the manganese
ion activated MtMetAP1c in a low micromolar concentration range (0.4-1.3 µM) and had
no potency with Ni2+-form of MtMetAP1c [Lu et al., 2011]. Olaleye et al. however,
discovered 2,3-dibromo-1,4-naphthoquinone [Olaleye et al., 2010], 7-bromo-5chloroquinolin-8-ol analogues [Olaleye

et al., 2011], 2-hydroxy-1-naphthaldehyde

isonicotinoyl hydrazone [John et al., 2016] exhibited an IC50 of 0.71 ± 0.02 µM, 3.76 mM
- 5.44 µM, 5.3 ± 1.8 µM respectively against Co2+ activated MtMetAP1c respectively, and
the group performed a MtMetAP1s metal dependence screen for cobalt (II) and Nickel(II)
and discovered both metals activated MtMetAP1c [Olaleye et al., 2016]. Bhat et al.
discovered Co2+ and Mn2+ displayed the highest activation of MtMetAP1c, and three
methanimidamides analogs derived from structure-activity modifications of N’-hydroxyN-(naphthothiazolyl) methanimidamide were shown to be effective in in vitro inhibiting
the activity of Co (II) metallated MtMetAP1c, the most potent analog inhibited the cobaltform of MtMetAP1c at an IC50 of 730nM but unfortunately the in vitro potency did not
translate to a good MIC value against Mtb [Bhat et al., 2012]. In another study, Lu et al.
investigated the X-ray structures of MtMetAP1c-compound bound complex and
discovered compounds 7 and 8 both bound to the Mn2+ and both Ni2+ and Co2+ metallated
MtMetAP1c [Lu et al., 2012]. By structurally modifying 3-amino-N-(thiazol-2-yl)
pyrazine-2-carboxamides parent compound Juhás et al. discovered the compound analogs
are dependent on the cofactor of the enzyme. The findings show different IC50 values
against the MtMetAP1a activated with cobalt, nickel, and iron ions [Juhás et al., 2022].
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These findings support the earlier discussion about the importance of designing a potent
MtMetAP1inhibitor based on the knowledge of the specific metal ions that, on the one
hand, are specific for the activation of MtMetAP1s and, on the other hand, can potentially
interact with prospective inhibitors. OJT008 target tree is the Metalloprotease M24A
subfamily of protease inhibitors and was patented by Olaleye et al. as a Methionine
Aminopeptidase Inhibitors for Treating Infectious Diseases. Olaleye et al. successfully
characterized OJT008 as a potent Antileishmanial Methionine Aminopeptidase 1 Inhibitor.
They performed both in vivo and in vivo assays to discover the compound is both effective
and potent against methionine aminopeptidase 1 of L. major, and OJT008 significantly
decreased the footpad parasite load in L. major infected mice model. In addition, the safety
of the compound was ascertained; OJT008 was non-toxic to intraperitoneal murine
macrophages [Rodriguez et al., 2020].
4.5 In silico evaluation of the mechanism of action of OJT008 against MtMetAP1c
A Molecular docking (in silico) analysis was conducted to evaluate the binding of OJT008
to MtMetAP1c with divalent metal ions (cobalt and nickel) bound to its active site. The
binding mode and docking scores at the MtMetAP1c active site were investigated and
estimated, respectively.
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Table 13. Molecular Docking Score of OJT008 towards the active site of Metal-bound
MtMetAP1c
Co-Enzyme

Docking Scores

MtMetAP1c+CoCl2

MtMetAP1c+NiCl2

-6.52

-7.01

(Kcal/mol)

An insignificant increase in the docking score of the pharmacophore in the presence of
cobalt ion (-6.52 Kcal/mol) compared to the docking score in the presence of nickel ion (7.01 Kcal/mol). The relatively high docking scores above signify the high blinding
propensity of OJT008 with MtMetAP1c having the two metal ions in its active site. This
confirms the in vitro inhibitory effect of OJT008 against MtMetAP1c. The docking scores
portray the change in potential energy when a protein and ligand interact. Conventionally
the more negative value of the docking score corresponds to a stronger affinity binding of
ligand to protein, while a lesser negative or positive value depicts lower binding of ligand
to a protein target.
In this report, an in silico evaluation conducted discovered OJT008 interacted with both
cofactors and the following amino acid residues; His (100), His (114), Thre (94), His (202),
Phe (211), and Cys (105). Recently, computational approach methods have been adopted
in the hit identification and lead optimization of drug discovery processes [Patrick et al.,
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1998; Langer T., & Hoffmann 2001; Bajorath, 2002]. Receptor-ligand plots were
performed to investigate the interactions of the amino acid residues, the metal ions at the
active site of the target enzyme molecule, and OJT008 [Kehinde et al., 2019; Shode et al.,
2021]. In this project, OJT008 was discovered to be highly sequestered in the highly
conserved MetAP pita-bread fold [Lowther., & Matthews., 2000; Lu et al., 2010b] Figure
25.

Figure 26. The 2-D visualization plot of MtMetAP1c -OJT008 interactions plots with
the following divalent metals bound a) CoCl2 and b) NiCl2 to MtMetAP1c.
Previous studies report MetAP inhibitors interact with divalent metals at the active site of
MetAP [Addlagatta et al., 2005; Lu & Ye et al., 2010a; Lu et al., 2010b]. Similarly, this
study reported identical interactions of OJT008 with Ni2+ and Co2+. The interaction
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between the inhibitor, 3-[(4-fluorobenzyl) sulfanyl]-4H-1,2,4-triazole (T03) [Lu et al.,
2010] and MtMetAP1c in a previous study were identical to OJT008 interaction with
MtMetAP1c reported in this project. The compound displayed similar types of interaction
bonds such as hydrogen bond, p-sigma, p-cation, p-Sulfur, p-alkyl, p-p stacked interaction,
donor-donor interactions, and Van der Waals (vdW) overlaps) observed [Lu et al., 2010b].
This finding further proves OJT008 an potent inhibitor of MtMetAP1c enzymeIn another
study, bengamide derivatives were also discovered to bind to Co2+in the active site of
MtMetAP1c.
In the Metalloprotease M24A subfamily of enzyme, a divalent metal like zinc, copper,
cobalt, or manganese activates a molecule of water. Also, the divalent metal is held in the
active site of the enzyme by majorly three amino acid residues. In the co-catalytic
metalloprotease family, five amino acid residues form bonds with two metal ions. The
residues are usually Glu, His, Lys, or Asp, and at least one of the amino acid molecules is
required for the catalytic function of the protease [Neil et al., 2013]. The MetAPs have a
homologous catalytic domain with conserved amino acid residues at their active sites
[Lowther & Matthews, 2000]. The five conserved amino acid residues are utilized by
MetAPs for metal ion coordination. This peculiarity poses a difficulty in the development
of selective MetAP inhibitors. Hit discovery and lead optimization in drug discovery
recently adopted the computational approach, which evaluates the complementarity to
binding of compounds and drug candidates to active sites of target enzymes. The results
from the molecular docking (in silico) analysis and protein-ligand interaction plot suggest
OJT008 as a potent inhibitor of MtMetAP1c nickel and cobalt ion metalloform.
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4.6 Determination of the potency of OJT008 against drug-sensitive Mtb and
Multidrug resistant- TB
In collaboration with Dr. Graviss's laboratory at Houston's Methodist research institute.
Texas. OJT008 potency against both drug-sensitive Mtb (CDC 1551 strain) and
Multidrug-resistant TB Mtb (HN 3409 strain). The compound displayed inhibition of the
growth of both drug-sensitive Mtb CDC 1551 strain and Multidrug-resistant-TB Mtb HN
3409 strain at ˂ 0.063 µg/mL Table 13.
Table 14. The potency of OJT008 against drug-sensitive Mtb and Multidrug-resistant
Mtb
Minimum inhibitory concentration (µg/mL)

OJT008

Drug-sensitive Mtb
(CDC 1551 strain)

Multidrug-resistant Mtb
(HN 3409 strain)

<0.063

<0.063

Isoniazid and kanamycin were used in the compound screen as the positive control with a
MIC value of 0.2µg/mL and 5.00 µg/mL. In this evaluation, OJT008 MIC values against
both drug-sensitive Mtb and MDR-Mtb (˂ 0.063 µg/mL = ˂ 0.194 µM) was 207-fold and
61-fold respectively more potent than the IC50 values against 100µM NiCl2 and CoCl2
activated MtMetAP1c; IC50 for MtMetAP1c-Ni2+metalloform: 40µM and MtMetAP1cCo2+ metalloform: 11 µM. The potency of OJT008 against Mtb was higher than it’s in vitro
inhibitory effect against MtMetAP1c. Several studies were conducted to determine the
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MIC values of compounds against different types and strains of Mtb in vitro. Numerous
pyrazine-containing compounds were discovered to have antimycobacterial activity
against Mtb [Juhás et al., 2020; Jandourek et al., 2017; Semelkováet al., 2017; Zitko et al.,
2018; Bouz et al., 2019]. Moderate potency was discovered for pyrazinecarboxamides
analogs against Mtb [Dolezal et al., 2006]. Olaleye et al. studies discovered promising
antimycobacterial compounds against drug-sensitive and non-replicating Mtb [Olaleye et
al., 2010; Olaleye et al., 2011, John et al., 2016]. Lu et al. discovered that one bengamide
derivative exhibited a moderate potency of 50.6 μM against drug-sensitive Mtb. Bhat et al.
discovered two fractions of bengamide derivatives were potent against both drug-sensitive
Mtb and non-replicating Mtb in the nanomolar concentration range; (SN31863) 0.39 µg/mL
and (SN31927) 1.56 µg/mL [Quan et al., 2019]. In some studies, there is a notable potency
correlation between the assayed compound in vitro effect against the purified MtMetAP
and the Mtb growth [Olaleye et al., 2010; Olaleye et al., 2011].
In another study compound's MtMetAP1s inhibition does not correlate with MIC values
reported [Bhat et al., 2012]. These discrepancies can be attributed to the poor absorption
of the compound into the bacteria membrane or the intrinsic efflux mechanism of the cells
reducing the intracellular concentration of the inhibitors [Rossi et al., 2006; Nguyen &
Pieters et al., 2009].
In the investigation, the OJT008 potency against drug-sensitive Mtb and MDR-Mtb was
207-fold and 61-fold higher than it’s inhibitory effect of the two metalloform MtMetAP1c
(MtMetAP1c- Ni2+ and MtMetAP1c- Co2+ respectively). Interestingly, our results show
that OJT008 is 4-fold and 6.6-fold more potent the isoniazid (MIC for Mtb CDC1551
strain: 0.25 µg/mL) [Vilchèze et al., 2018] and rifampicin (MIC for Mtb CDC1551 strain:
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0.41µg/mL) [Yang et al., 2020] which are the first-line TB drug for drug-sensitive Mtb
respectively. Also, OJT008 was discovered to be about 80-fold (5 µg/mL) more potent than
the standard antibiotic for treating MDR-Mtb strain.
The difference in the potency of the compound against the enzyme in vitro and in Mtb
could be attributed to the difference in the substrate present in Mtb cells and the
biochemical substrate analog used for the in vitro enzymatic assay. A plausible suggestion
could be that OJT008 targets another Mtb genome, which encodes for about 4,000 genes
[Cole et al., 1998], besides the mapB gene in the Mtb types screened. Another explanation
for the comparatively lower OJT008 potency against purified holo-form MtMetAP1c could
be attributed to the excess metal ions or imidazole impurities inhibitory effect [Zhang et
al., 2009]. A possible source of metal impurity could be the Ni-NTA Resin, used to purify
the expressed MtMetAP1c and the native metal ions present in the E.coli BL21 DE3
competent cells used as the host cell for the overexpression of the target enzyme. In
addition, the imidazole, a chelating agent [Yamauchi

et al., 1968; Yip., & Hutchens.,

1994] used for eluting MtMetAP1c, can also chelate the Ni2+ and Co2+ used to activate
MtMetAP1c. These factors can contribute to the higher representative IC50 reported in this
project. Although, as stated earlier, Narayanan et al. studies also discovered that 100 µM
of both Nickel and cobalt ions produced a maximum activation of the apo-form
MtMetAP1c [Narayanan et al., 2012]. Dialysis of the eluted MtMetAP1c should be done
to strip the pure enzyme of possible impurities prior to conducting the OJT008 inhibitory
effect on the metalloprotease to accurately represent the activity and potency of the
compound against the enzyme.

CHAPTER 5

SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
Tuberculosis (TB) is classified as the 13th leading cause of death globally [WHO, 2021].
Before COVID-19, TB was the foremost cause of death arising from a single infection
globally [WHO, 2021]. An estimated 25% world population is infected with latent TB,
which implies 1 in 4 persons have an asymptomatic, non-infectious TB [WHO, 2021].
Approximately 13 million people had latent TB infection in the United States in 2020, and
about 10% of this population can develop active TB in their lifetime [CDC,2021]. Despite
the advance in TB research, the challenges of eradicating TB disease are further
complicated due to the emergence of Mtb to resistant standard current anti-TB therapy.
These include multidrug-resistant, extensively, and totally drug-resistant strains of Mtb
[Cole et al., 1998; Fauci et al., 2008; Shelley et al., 2010]. It is crucial to develop
antimycobacterial that inhibit novel Mtb drug targets and mechanisms of action
[Theuretzbacher et al., 2019]. Another factor to consider in obtaining an efficient TB
medication compliance is considering novel antimycobacterial that will constitute less pill
burden and reduce the duration of the drug regimen. Therefore, the study focused on
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characterizing a novel therapeutic agent that will be therapeutically potent against both
wild and resistant types of Mtb. In this project, a combination of genetic, biochemical
assay, computational, and microbiological approaches to characterize OJT008 as an
inhibitor of Mtb targeting MtMetAP1c. This was achieved by evaluating the in vitro
inhibitory effect of OJT008 against MtMetAP1c, evaluating the mechanism of inhibition
of the compound against the protease-activated with divalent metals, and the
antimycobacterial effect of OJT008 against drug-sensitive Mtb strain and MDR-TB Mtb
strain was investigated.
In other to successfully determine the inhibitory effect of OJT008 against MtMtAP1c, the
target protease was generated in the laboratory. In this study, mapB was amplified from
the Mtb H37Rv genome using the PCR technique. Successively, the target gene and vector,
pET28a, was successfully digested through a double restriction enzyme digestion protocol.
The digested DNAs were prepared in molar DNA ratios of 7:1 and 5:1 and ligated to form
the target recombinant DNA using the T4 DNA Ligase. The expression E.coli competent
cells, DH5 alpha competent cells, were utilized in generating copies of recombinant target
genes. The mutant free recombinant plasmid was used to transform an E. coli expression
host, E. coli BL21 DE3, and the target protease was overexpressed using 1mM IPTG. The
expressed protease was purified, and a Preliminary evaluation of MtMetAP1c dependence
on divalent metal ion: Nickel2+ and cobalt

2+

was performed. The protease metal

107
dependence screen showed that an optimum activity of MtMetAP1c was achieved at 100
µM of both divalent metal ions. OJT008 was discovered to inhibit the activity of
We conducted an investigation of the inhibitory effect of OJT008 against the activity of
CoCl2 and NiCl2 (100µM) activated MtMetAP1c at a low micromolar concentration. An
in silico study was studied to determine OJT008’s mechanism of inhibition of the
metalloform MtMetAP1c. The high negative binding score values depicted the strong
inhibiting effect of the compound against nickel and cobalt ion activated MtMetAP1c. The
inhibitory effect was also confirmed by receptor-ligand plots, which show a strong
molecular interaction of the pharmacophore with the conserved amino acid residue and
bound divalent metal at the active site of MtMetAP1c. To determine the potency of OJT008
against both drug sensitive Mtb and MDR-TB strain of Mtb, we collaborated with the
Methodist research institute, Houston. Texas to screen the in vitro inhibitory effect of the
pharmacophore against the Mtb strains. The compound inhibited the growth of both drugsensitive Mtb CDC 1551 strain and Multidrug-resistant-TB Mtb HN 3409 strain at ˂ 0.063
µg/mL. This study shows a promising potency of OJT008 against the MDR-TB, thereby
strategically positioning OJT008 as a promising antimycobacterial pharmacophore against
TB cases resistant to first line TB treatment. The significance of our study is the potential
characterization of a novel chemotherapeutic agent against active and MDR-Mtb, thereby
overcoming the challenges of the current TB drug regimen. In addition, the compound’s
utilization of MtMetAP1c as a potential chemotherapeutic target poses the benefits of
circumventing the global challenges posed by multidrug-resistant (MDR) and drug-
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sensitve TB. Therefore, OJT008 can serve as a propitious lead to discovery and
development of novel antimycobacterial agents. This compound will be promising in the
treatment of TB and as well serve as a prerequisite towards the development of inhibitors
MtMetAP1c upon additional in vivo and clinical evaluations. Future consideration includes
dialyzing the eluted MtMetAP1c to it’s apoenzyme state prior to determining the enzyme
metal dependence and the in vitro inhibitory effect of the compound against MtMetAP1c.
Another recommendation is to perform the MtMetAP1c metal dependence activity with
more divalent metals such as manganese, iron, and zinc. In this project, we screened the
potency of OJT008 against Mtb using a final concentration range of 50 - 0.0625 µg/mL.
The discovered MIC values for Mtb strains were 0.0625 µg/mL. It is recommended to
screen the potency of the compound at a lower concentration should also be used in
evaluating the potency against Mtb to determine the specific MIC value of the compound.
The cytotoxicity and safety profiles of OJT008 against mammalian cells should be
conducted. Finally, another recommendation is to conduct a preclinical study to evaluate
the potency of OJT008 on both TB drug sensitive and resistant mouse model. Further
structural modification of this pharmacophore to increase the in vitro and in vivo potency
of OJT008 is recommended.
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